

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Face-to-face and online cognitive behavioral therapy for traumatically bereaved people: Study protocol for a randomized waitlist controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035050
Article Type:	Protocol
Date Submitted by the Author:	16-Oct-2019
Complete List of Authors:	Lenferink, Lonneke; Rijksuniversiteit Groningen, de Keijser, Jos; Rijksuniversiteit Groningen Eisma, Maarten Smid, Geert Boelen, Paul; Utrecht University
Keywords:	PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Face-to-face and online cognitive behavioral therapy for traumatically bereaved people:**
4

5 **Study protocol for a randomized waitlist controlled trial**
6
7

8 Lenferink, L.I.M.*^{1,2}, de Keijser, J.¹, Eisma, M.C.¹, Smid, G.E.^{3,4,5}, & Boelen, P.A.^{2,3,4}
9
10

11
12 ¹ Department of Clinical Psychology and Experimental Psychopathology, Faculty of
13 Behavioral and Social Sciences, University of Groningen, Grote Kruisstraat 2/1, 9712 TS
14 Groningen, The Netherlands. E-mail L.I.M. Lenferink: l.i.m.lenferink@rug.nl.
15
16

17
18
19
20 ² Department of Clinical Psychology, Faculty of Social Sciences, Utrecht University, P.O. Box
21 80140, 3508 TC, Utrecht, The Netherlands.
22
23

24
25
26 ³ ARQ National Psychotrauma Centre, Nienoord 5, 1112 XE, Diemen, The Netherlands
27
28

29
30 ⁴ Foundation Centrum '45, Nienoord 5, 1112 XE Diemen, The Netherlands
31

32
33 ⁵ University of Humanistic Studies, Utrecht, The Netherlands
34
35

36 *Corresponding author
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

The sudden or violent death of a significant other, such as death due to a traffic accident, can precipitate persistent complex bereavement disorder (PCBD) and comorbid posttraumatic stress disorder (PTSD) and depression. Waitlist controlled trials have shown that grief-specific cognitive behavioral therapy (CBT), delivered face-to-face or online, is an effective treatment for mental health problems. This is the first study that will examine 1) the effectiveness of CBT in a sample exclusively comprised of people bereaved by a traumatic death and 2) the effectiveness of face-to-face CBT (vs. waitlist controls) *and* online CBT (vs. waitlist controls). Our primary hypothesis is that people allocated to the face-to-face or online CBT condition will show larger reductions in PCBD, PTSD, and depression symptom levels post-treatment than people allocated to a waitlist. We further expect that treatment effects are mediated by reductions of negative cognitions and avoidance behaviors and moderated by accident-related stressors. Lastly, the associations between therapeutic alliance and treatment outcomes will be explored.

Methods and analysis

A three-arm (face-to-face CBT, online CBT, and waiting list) open label parallel randomized controlled trial (RCT) will be conducted. Participants will complete questionnaires at pre-treatment and 12 and 20 weeks after study enrolment. Eligible for participation are Dutch adults who lost a family member, spouse, or friend at least one year earlier due to a traffic accident and report clinically relevant levels of PCBD, and/or PTSD, and/or depression. Multilevel modeling will be used for the main analyses.

Ethics and dissemination

Ethical approval has been received (METc UMCG:2019.233). If the treatments are demonstrated to be effective, both treatments will be available for future bereaved people. Findings will be disseminated among lay people (e.g., newsletters), our collaborators (e.g., through presenting at non-governmental/(peer-)support organizations), and clinicians and researchers (e.g., (inter)national conferences/journals).

Keywords: bereavement; grief; trauma; PTSD; treatment; intervention.

Strengths and limitations of this study

- This study is the first to examine the effectiveness of face-to-face CBT (vs. waitlist controls) and online CBT (vs. waitlist controls) in reducing psychopathology after traumatic loss in a three-arm RCT.
- This treatment study is one of the first to examine potential moderators and mediators of change in symptom levels after traumatic loss.
- We are not able to statistically test if CBT offered face-to-face or online has equal effects, because limited resources do not allow for recruitment of very large samples.
- Another limitation is the use of self-report questionnaires, instead of diagnostic interviews, to assess symptom levels.

Trial registration number

NL7497 (Dutch Trial Register)

Word Count: 5,017 words including main text

Introduction

Worldwide, traffic accidents represent the leading cause of unnatural death[1]. Ten to 20% of bereaved people develop severe and persistent grief-related distress, including persistent complex bereavement disorder (PCBD), posttraumatic stress disorder (PTSD), and depression after natural deaths (e.g., illness)[2,3]. Notably, PCBD has been introduced, as other specified psychotrauma- and stressor-related disorder, in the latest version of the Diagnostic and Statistical manual of Mental Diseases (DSM-5)[4]. PCBD is diagnosed if, after the death of a significant other at least 12 months earlier, the person experiences persistent yearning for the deceased and symptoms of reactive distress (e.g., emotional numbness) and social/identity disruption (e.g., feeling alone) causing impairment in daily life. While some PCBD symptoms overlap with PTSD (e.g., anger) and depression symptoms (e.g., sadness), several studies have shown that these three syndromes are distinct[5–7].

Unexpected/violent losses of a significant other, also referred to as a traumatic losses, including deaths caused by traffic accidents, render a risk for developing PCBD, PTSD, and depression[8,9]. The co-occurrence of (symptoms of) these disorders following traumatic loss has also been referred to as “traumatic grief”[10].

Increased risk for developing psychopathology after deaths due to traffic accident

Specific circumstances of losses caused by accidents may account for the elevated risk of traumatic grief. For instance, experiencing multiple losses simultaneously, being a witness to the accident, and juridical and financial consequences are presumed to exacerbate grief-related distress[11]. Furthermore, negative cognitions and avoidance behaviors may mediate the impact of sudden/violent loss on grief, PTSD, and depression levels[12].

According to a cognitive-behavioral model of complicated grief, three interacting malleable

1
2
3 processes underlie disturbed grief reactions: i) negative cognitions, ii) avoidance behavior,
4
5 and iii) difficulties integrating the loss into the autobiographical knowledge base[13].
6
7

8
9 Experiencing a loss due to a traffic accident may violate basic assumptions about the
10 world being a safe place[14]. This may fuel negative cognitions (e.g., “I’m less worthy, since
11 s/he died” and “The death of him/her has taught me that the world is unjust) that may
12
13 exacerbate and maintain acute grief responses[15]. Avoidance behaviors include depressive
14
15 avoidance and anxious avoidance strategies. Depressive avoidance refers to withdrawal from
16
17 social and occupational activities that were perceived as fulfilling before the death, out of
18
19 the conviction that these activities are no longer meaningful. Anxious avoidance strategies
20
21 serve to prevent confrontation with the reality of the death, out of fear that confrontation is
22
23 too painful[13]. One way to avoid confrontation with the reality of the loss, is to focus on
24
25 angry thoughts and feelings (e.g., “I was angry at the police, courts, or administration,
26
27 because they did not do their work well enough”)[16]. This seems to be a frequently used
28
29 avoidant coping strategy in bereaved people after traffic accidents and is strongly related to
30
31 PTSD[17]. Difficulty with integration of the loss into the autobiographical knowledge base
32
33 refers to the difficulties connecting factual knowledge that the loss is irreversible with
34
35 existing information about the self and the relationship with the lost person, stored in
36
37 autobiographical memory. Memories related to the loss may lack context in terms of time
38
39 and place, causing the loss to be experienced as unreal[18]. It has been argued that this
40
41 “sense of unrealness” may trigger intrusive memories and increase feelings of numbness or
42
43 shock once the bereaved person is confronted with reminders of the loss[18,19]. The extent
44
45 to which a person believes that one is capable of managing stressor-related thoughts,
46
47 emotions, and behaviors, also referred to as self-efficacy (e.g., “I can usually handle
48
49 whatever comes my way”), has also been determined as an important factor facilitating
50
51
52
53
54
55
56
57
58
59
60

1
2
3 coping with traumatic stressors[20]. Decreased self-efficacy, negative cognitions and
4
5 insufficient integration of the loss may contribute to increased sensitivity to loss reminders
6
7 or secondary stressors following traumatic loss[10].
8
9

10 *Face-to-face cognitive-behavioral therapy for grief-related distress*

11
12 Grief-specific CBT has, so far, proven to be the most effective treatment for bereaved people
13
14 with elevated grief levels[21–24]. CBT targets the above-mentioned cognitive-behavioral
15
16 variables with cognitive restructuring, loss-related exposure, and behavioral activation.
17
18 Notably, research on putative mechanisms of change of grief-specific CBT is sparse[23] (but
19
20 see[25,26]). Focusing on people with traumatic grief is relevant because it would enable
21
22 tailoring of interventions to the specific needs of this group, which could improve treatment
23
24 outcomes[27].
25
26
27
28
29
30

31
32 Studies evaluating the effectiveness of CBT-based interventions for people bereaved
33
34 by sudden/violent deaths have been conducted earlier, but these were often designed to
35
36 target high risk groups irrespective of symptom levels (e.g., people bereaved by suicide[27];
37
38 see also:[24]). Since interventions for people without mental health complaints following
39
40 loss do not appear to be effective[28], it is critical to specifically examine the effectiveness of
41
42 CBT in groups who experience traumatic grief. While some studies did so, these tested the
43
44 effectiveness of CBT with additional interventions, such as group interventions or eye
45
46 movement desensitization and reprocessing[29,30]. It is therefore yet unclear if application
47
48 of CBT in and of itself is effective in reducing psychopathology in people with traumatic grief.
49
50
51
52
53

54 *Face-to-face and online cognitive behavioral therapy for grief-related distress*

1
2
3 Whilst the majority of trials assess the efficacy of face-to-face CBT[24], some online CBT-
4 based interventions have been developed for distressed bereaved people[31–33]. Offering
5 CBT through the internet has some potential advantages. It may lower the threshold for
6 seeking treatment, because it can be delivered independent of geographical location.
7
8 Furthermore, asynchronous communication may be used, allowing the client and therapist
9 can contact each other at any preferred time[34]. This may counter barriers to mental health
10 service use, such as difficulties with finding help, transportation concerns, or difficulties
11 scheduling treatment sessions[35]. In addition, online CBT could reduce treatment costs,
12 improving its accessibility and dissemination for people in need of support[36].
13
14

15
16
17
18
19
20
21
22
23
24
25
26 A potential downside to online CBT is the high dropout rates found in earlier
27 studies[36,37]. It has been argued that a strong therapeutic alliance might support
28 adherence to online treatment and mediates treatment effects [38]. Therapeutic alliance is
29 defined as a positive emotional bond between client and therapist, whereby both parties
30 agree on the tasks and goals of the treatment[39]. A good client-therapist relationship might
31 also explain why guided are more effective than unguided online treatments[34]. Concerns
32 have been raised that developing a therapeutic relationship might be more difficult when
33 non-verbal communication is absent[40]. Studies in non-bereaved samples indicate that
34 developing a strong therapeutic alliance is possible during online treatment[36], and this has
35 been found to be related to online treatment outcomes[41], but see Andersson and Titov
36 (2014). More research is needed to further examine the potential differences in quality of
37 client-therapist relationship between face-to-face and online CBT and its relationship with
38 treatment outcomes.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 *Study objectives*
59
60

1
2
3 Our first aim is to examine the effectiveness of face-to-face CBT (vs. a waiting list control
4 condition) and online CBT (vs. a waiting list control condition) in reducing symptom levels of
5
6 PCBD, PTSD, and depression in people bereaved by a traffic accident. We expect that
7
8 participants assigned to the face-to-face and the online CBT conditions will show larger
9
10 reductions in symptom levels of PCBD, PTSD, and depression compared with waitlist controls
11
12
13 at post-treatment assessments (Hypothesis 1).
14
15
16

17
18 Our second aim is to explore potential mediators of therapeutic effects. Based on
19
20 prior research and theorizing[13,17,20], we expect that reductions in negative cognitions,
21
22 avoidance behaviors, state anger, a sense of unrealness, and improvement in self-efficacy
23
24 mediate the positive effects of face-to-face (vs. waiting list controls) and online CBT (vs.
25
26 waiting list controls) (Hypothesis 2a). In addition, our aim is to explore whether background
27
28 characteristics (i.e., gender, age, and educational level, kinship to the deceased, and time
29
30 since loss) and accident-related stressors (i.e., single vs. multiple loss, witnessed the
31
32 accident, and involvement in legal trial) moderate treatment effects (Hypothesis 2b). We
33
34 have no specific expectations regarding these associations because prior treatment studies
35
36 in bereaved people showed inconsistent results[24,25,30]. However, based on clinical
37
38 experience, we expect that accident-related stressors will moderate treatment effects, such
39
40 that multiple loss, witnessing the accident, and involvement in legal trial negatively impact
41
42 treatment effects.
43
44
45
46
47
48
49

50
51 Our third aim is to explore i) potential differences between the face-to-face and
52
53 online CBT condition in therapeutic alliance (as perceived by the participant and therapist)
54
55 and (ii) the associations between quality of the therapeutic alliance and treatment
56
57
58
59
60

1
2
3 outcomes. Because prior research findings in this area are not equivocal[36,41], no specific
4
5 hypotheses were formulated.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Methods and analysis

Design


A three-arm (face-to-face CBT, online CBT, and waiting list) multi-centre open label parallel RCT will be conducted in the Netherlands. Randomization will take place after the participant is screened for eligibility-based inclusion criteria (described below). A random number generator (www.random.org) will be used by a blinded independent researcher, to perform the blocking randomization procedure. An allocation ratio of 1:1:1 will be applied.

Participants allocated to the face-to-face or online CBT condition receive treatment within one week after allocation. All participants will be asked to fill in questionnaires (described below) at baseline (T1), 12 weeks post-allocation (T2), and 20 weeks post-allocation (T3). For participants in the waiting list control group, T3 is at the end of the 20-week waiting period after which they will be randomly allocated to receive face-to-face or online CBT (see Figure 1). A waiting list control group (instead of a no treatment control group) is included to increase the likelihood of participation by guaranteeing that all participants receive treatment. Furthermore, the inclusion of a waiting list control group allows a treatment versus no treatment comparison, that will provide knowledge about the effects of treatment relative to natural recovery from loss. We chose to randomly allocate waitlist controls to face-to-face or online CBT after the 20-week waiting period to maximize the sample size needed for the third research aim.

In line with prior treatment studies from our research group[30,42], the face-to-face CBT is carried out at the institution or private practices of licensed and registered psychologists who are a member of our Traumatic Loss Network (i.e., informal national network of trauma and grief therapists that are involved in research projects of our research

group). All psychologists will receive an 8-hour training about the treatment protocol of this intervention study. The personalized therapist feedback in the online CBT will also be provided by members of the Traumatic Loss Network. The treatment costs in both conditions will be reimbursed.

Figure 1. RCT design



Note. CBT = cognitive-behavioral therapy

Participants

This RCT is part of a larger on-going research project (so termed "TrafVic-project") examining the psychological impact of, and care after, the death of a significant other due to a traffic accident. We expect to recruit the majority of the participants via a survey-study that has started in December 2018 that included the following question: "In this study we would like to offer psychological help to persons who experience emotional problems. May we approach you with more information about this offer, if your answers to this questionnaire imply that you may experience emotional problems?" People who answered 'yes' will receive a letter with information about the intervention, the treatment study, and an informed consent form. A website (www.rouwnaverkeersongeval.nl) has been developed so

1
2
3 that potential participants can read information about the research and treatments. People
4
5 who are interested can also sign up for the study via this website. Recruitment for this RCT
6
7 had not started at the time of submission of this manuscript.
8
9

10
11 To be eligible for study participation, the person must 1) be a family member,
12
13 spouse, or friend of a person who died due to a traffic accident at least one year earlier, 2)
14
15 be ≥ 18 years of age, and 3) meet DSM-5 criteria for PCBD and/or PTSD and/or experience
16
17 clinically relevant depression, based on questionnaire scores (see below for more details).
18
19 People are excluded when they: 1) do not master the Dutch language, 2) do not have access
20
21 to Internet, 3) suffer from a substance use disorder, psychotic disorder, intellectual
22
23 disability, and/or suicidality based on clinical judgment at the intake.
24
25
26
27
28

29 **Sample size**

30
31
32 To test our primary hypothesis (Hypothesis 1), two tests for each outcome separately (PCBD,
33
34 PTSD, and depression) will be conducted, with test 1 examining face-to-face CBT vs. waitlist
35
36 controls and test 2 examining online CBT vs. waitlist controls. To find a difference between
37
38 controls and test 2 examining online CBT vs. waitlist controls. To find a difference between
39
40 two groups (face-to-face CBT vs. waitlist controls and online CBT vs. waitlist controls) of at
41
42 least a medium effect size ($f = 0.25$; based on prior research[22,30,31]) with a power of 80%,
43
44 an α of 0.017 (corrected for multiple testing, i.e., $0.05/3$, because of three primary outcome
45
46 measures (PCBD, PTSD, and depression)), and a strong association ($r = .50$) between the
47
48 three repeated measures (T1, T2, and T3), a sample size of 23 per condition is sufficient.
49
50 Taking into account an average dropout rate of 19% [22], a total sample size of 82 (69+13) is
51
52 required to test Hypothesis 1.
53
54
55
56

57
58 Because our data are nested (repeated measures) (level 1) within individuals (level
59
60 2), and possibly within families sharing the same household (level 3), multi-level modeling

1
2
3 will be performed to test hypothesis 1. Conducting a power analysis within a multi-level
4
5 framework is not feasible for various reasons[42]. We therefore conducted the power
6
7 analysis for a repeated measures ANOVA.
8
9

10 **Intervention**

11
12
13
14 CBT will consist of eight sessions offered in within a timeframe of 12 weeks. Eight sessions
15
16 have shown to be sufficient to yield clinically relevant effects in prior research[30]. Following
17
18 Dutch guidelines for grief-specific CBT[43], central components of the treatment are
19
20 exposure, cognitive restructuring, and behavioral activation. In the first session,
21
22 psychoeducation is offered, including information about possible emotional reactions to the
23
24 death of a loved one in a traffic accident and processes that might foster or hamper
25
26 recovery. A rationale for the CBT interventions is provided.
27
28
29
30
31

32
33 Then, session 2, 3, and 4 are focused on exposure; the circumstances and story of the
34
35 loss are discussed in detail, and the participant is encouraged to confront stimuli that s/he
36
37 tends to avoid. Exposure is conducted by imaginary exposure assignments in session and
38
39 after the session by writing assignment that have proven effective in prior research[33].
40
41 These writing assignments are focused on writing a detailed narrative of the loss and its
42
43 circumstances.
44
45
46
47

48
49 The next sessions (5 and 6) focus on identifying and changing negative cognitions
50
51 that hamper adjustment (i.e., cognitive restructuring); specific attention is paid to cognitions
52
53 connected with responsibility/guilt and anger that may be elevated following the accidental
54
55 death[11]. Cognitive restructuring assignments are provided to gain an alternative
56
57 perspective on negative thoughts about the self, life, the future, by 1) psycho-education
58
59 about common unhelpful thoughts, 2) identifying one's own unhelpful thoughts, and 3)
60

1
2
3 challenging these thoughts. Participants are instructed to undertake these three steps by
4
5 writing down each day a description of i) an emotional moment/event, ii) their thoughts
6
7 during this event, iii) their feelings (and intensity of these feelings on a scale of 1 through
8
9 10), iv) their behavior, v) evaluation of their thoughts), and vi) alternative helpful thoughts.
10
11
12

13
14 In session 7 and 8, participants are encouraged to reengage in previously valued
15
16 social, recreational, and occupational activities in order to facilitate the process of
17
18 adjustment. Behavioral activation assignments are focused on writing about valued activities
19
20 and making plans to achieve valued goals. Session 8 is also focused on what the participant
21
22 has learned and how to deal with difficulties in the future.
23
24
25

26
27 Online CBT uses the same interventions with the same goals, yet with all information
28
29 and assignments being presented in an online framework, offered via a secure website. As in
30
31 the face-to-face CBT, exposure, cognitive restructuring, and behavioral activation are
32
33 central. Instead of information being exchanged interactively between the therapist and the
34
35 participant, in online CBT, participants listen to a video-therapist verbally sharing
36
37 information. Similar to face-to-face CBT, the treatment includes 8 sessions, called lessons.
38
39 Participants receive weekly asynchronous written feedback from an online therapist on
40
41 assignments that they complete. In both conditions, participants receive written information
42
43 — offered in a treatment manual for face-to-face condition and offered online for the online
44
45 condition — that consists of psychoeducation, details about the content of the treatment,
46
47 and homework assignments. Moreover, in both conditions, participants are encouraged to
48
49 ask a significant other to support them during treatment. This support figure is then
50
51 informed about the treatment through written information.
52
53
54
55
56
57
58
59
60

1
2
3 Treatment adherence for the face-to-face CBT will be monitored by asking the
4
5 therapists to report compliances and deviations from the protocol in a journal. Adherence
6
7 for the online CBT will be monitored by evaluating log data. Monthly supervision of the
8
9 therapists takes place by telephone.
10
11
12

13 **Measures**

14 *Primary outcome measures*

15
16
17 PCBD is assessed with the Traumatic Grief Inventory-Self Report (TGI-SR)(44). The TGI-SR
18
19 consists of 18 items on a 5-point Likert scale ranging from 1 = never through 5 = always. Four
20
21 items tapping disturbed grief criteria according to the 11th edition of the International
22
23 Classification of Diseases were added(45). An example of an item is: "I found it difficult to
24
25 trust others". The instruction of the original questionnaire was altered from referring to "the
26
27 death of your loved one" to "the death of your loved one(s) due to a traffic accident".
28
29 Psychometric properties of the TGI-SR are adequate(44,46). Participants are considered as
30
31 meeting criteria for DSM-5 PCBD(4) when they score at least 3 ("Sometimes") on at least 1
32
33 criterion B symptom (Item 1, item 2, item 3, and item 14), at least 6 criterion C symptoms
34
35 (item 4 up to 11, and item 15 up to 18), and the criterion D symptom (item 13).
36
37
38
39
40
41
42
43
44

45 PTSD symptoms are assessed with the PTSD Checklist for DSM-5 (PCL-5)(47) (Dutch
46
47 version: (48)). Participants rate how often they were bothered by each symptom (e.g., "In
48
49 the past month, how much were you bothered by trouble remembering important parts of
50
51 the accident?") on 5-point Likert scales (0 = not at all and 4 = extremely). The instruction and
52
53 the items of the original questionnaire are altered from referring to the "stressful event" to
54
55 the "the death of your loved one(s) due to a traffic accident". The PCL-5 has shown to be
56
57 reliable and valid(47). Participants meet the criteria for DSM-5 PTSD(4) when they score at
58
59
60

1
2
3 least 2 ("Moderately") on 1 criterion B item (items 1-5), 1 criterion C item (items 6-7), 2
4
5
6 criterion D items (items 8-14), and 2 criterion E items (items 15-20).
7

8
9 Depression symptom are assessed with the depression subscale of the HADS-D(49).
10
11 The HADS-D consists of 7 items (e.g., "I still enjoy the thing I used to do") rated on 4-point
12
13 scores ranging from 0 (e.g., "Hardly at all") through 3 (e.g., "Definitely as much"). The Dutch
14
15 HADS-D is a reliable and valid screening tool for depression(50). A cut-off score of ≥ 8 is used
16
17 as indicator for clinically relevant depression(49).
18
19

20 21 22 *Secondary outcome measures*

23
24
25 Impairments in daily functioning is measured with the 5-item Work and Social
26
27 Adjustment Scale (WSAS)[51] (Dutch version:[52]). Participants rate, on 9-point Likert scales
28
29 (0 = not at all to 8 = extremely), how much they are currently impaired in, for instance work,
30
31 because of the death of their loved one(s) due to a traffic accident. The WSAS demonstrated
32
33 good reliability and validity[51].
34
35

36
37
38 Negative grief-related cognitions are assessed with 18 items from the Grief
39
40 Cognitions Questionnaire (GCQ)[15]. Participants are asked to rate their agreement with
41
42 each item (e.g., "Since [-] is dead, I feel less worthy") on 6-point scales varying from 0 =
43
44 disagree strongly through 5 = agree strongly. The psychometric properties have been
45
46 positively evaluated in prior research[15].
47
48
49

50
51 Avoidance is measured with the Depressive and Anxious Avoidance in Prolonged
52
53 Grief Questionnaire (DAAPGQ)[53]. The depressive avoidance subscale consists of 5 items
54
55 (e.g. 'Since [-] is dead, I do much less of the things that I used to enjoy.') and the anxious
56
57 avoidance subscale consists of 4 items (e.g., 'I avoid to dwell on painful thoughts and
58
59
60

1
2
3 memories connected to his/her death.’). Participants answer each item on an 8-point scale
4
5 with 0 = not at all true for me, and 7 = completely true for me. The DAAPGQ has adequate
6
7 psychometric properties[53].
8
9

10
11 State anger is assessed with the 15-item state anger subscale of the State-Trait Anger
12
13 Expression Inventory-2 (STAXI-2)[54] (Dutch version:[55]). Participants are asked to rate on
14
15 4-point Likert scales (1 = not at all and 4 = extremely) how angry they feel right now (e.g., “I
16
17 feel annoyed”). The STAXI-2 is a valid and reliable measure to assess state anger[55].
18
19

20
21 A sense of unrealness is measured with the 5-item Experienced Unrealness Scale[18].
22
23 Participants are asked to rate their agreement with each item (e.g., “I still can hardly imagine
24
25 that [-] will never be here again”) on 8-point scales (0 = not at all true for me 7 = completely
26
27 true for me). This instrument demonstrated adequate psychometric properties[18].
28
29

30
31 Self-efficacy is assessed with the General Self-Efficacy Scale (GSES)[56]. The GSES is a
32
33 10-item measure. Participants are asked to rate their agreement with each item (e.g., “I can
34
35 solve most problems if I invest the necessary effort.”) on a 4-point scales (1 = completely not
36
37 true, 4 = completely true). The GSES has shown excellent reliability and validity[56].
38
39

40
41 Quality of the therapeutic alliance is measured with the 12-item Work Alliance
42
43 Inventory-Short Form, Client Version and Therapist Version at session 4 (WAI-SF)[57] (Dutch
44
45 version:[58]. The WAI-SF consists of 12 items (e.g., Client version: “We agree on what is
46
47 important for me to work on”, Therapist Version: “We are working towards mutually agreed
48
49 upon goals.”) on 5-point scales (1 = never and 5 = always). Higher total scores indicate a
50
51 higher quality of the therapeutic alliance as perceived by the participant and therapist. The
52
53 WAI-SF is a reliable and valid assessment tool[59].
54
55
56
57
58
59
60

Other measures

Participants are allowed to receive other forms of psychosocial support during participation in the trial. Based on a single question we will assess whether the participants received other forms of psychosocial professional support in order to consider this in our analyses. The following question will be used: “During the past 12 weeks/8 weeks (for T2 and T3, respectively) did you receive additional psychological professional support from a psychologist, therapist or psychiatrist other than the (on-line) therapist from the TrafVic-study?” Other forms of support (for example instrumental and legal support) and the use of (psychotropic) medications are also allowed for every participant.

Statistical analyses

To examine the differences in reductions of symptom levels of PCBD, PTSD, and depression from pre- to post-treatment between the conditions (face-to-face CBT, online CBT, and waitlist), six independent multi-level models will be built (Hypothesis 1). Symptom levels of PCBD, PTSD, and depression will consecutively be included as dependent variables and condition (face-to-face CBT vs waitlist controls or online CBT vs. waitlist controls), time, and time x condition (interaction term) as predictor variables, taking into account that repeated observations (level 1) are nested within individuals (level 2), and within households (level 3; if applicable). Additionally, relevant background, loss-related variables, and use of co-interventions (yes/no) during participation in our study, will be included in the analysis as covariates. Deviance tests will be used to examine whether inclusion of these covariates improves model fit[60].

To test hypothesis 2a, mediation analyses will be conducted for the dependent variables that show a significant time x condition interaction effect. Each possible mediator

1
2
3 (i.e., negative cognitions, avoidance behavior, state anger, a sense of unrealness, and self-
4
5 efficacy) will be included in the model separately. Multiple mediation models will not be
6
7 examined, due to an anticipated lack of power. Scores at three measurement occasions (T1,
8
9 T2, and T3 for the face-to-face and online CBT and T1, T1a, and T1b for the wait list controls)
10
11 for the mediator and dependent variable will be taken into account in one structural
12
13 equation model following recommendations from Little[61].
14
15
16
17

18
19 To achieve research aim 2b, multilevel analyses will be used to examine to what
20
21 extent treatment effects on PCBD, PTSD, and depression levels are moderated by
22
23 background characteristics, including gender (man vs. woman), age (in years), and
24
25 educational level (low vs. high), kinship to the deceased (child/spouse vs. other), and time
26
27 since loss (in years), and b) accident-related stressors, including number of losses (single vs.
28
29 multiple), witnessing the accident (no vs. yes), and involvement in legal trial (no vs. yes).
30
31 Each possible moderator will be added to the model by including it as a predictor and as
32
33 interaction term (e.g., time x condition x gender).
34
35
36
37
38

39 For examination of the third research aim, T-tests will be used to explore to what
40
41 extent therapeutic alliance (total and subscale scores) differ between conditions (face-to-face
42
43 vs. online CBT). Lastly, therapeutic alliance scores will be added as predictor in multilevel
44
45 models to examine to what extent it interacts (i.e., time x condition x therapeutic alliance)
46
47 with treatment outcomes. Data of all participants entering the study will be included in all
48
49 analyses (i.e., intention-to-treat analysis).
50
51
52
53

54 **Ethics and dissemination**

55
56
57 This study has been approved by a local ethics committee (METc UMCG: ID number:
58
59 2019.233). The study will be conducted according to the principles of the Declaration of
60

1
2
3 Helsinki (8th version, 2013) and in accordance with the Medical Research Involving Human
4
5 Subjects Act. Collected data will be handled confidentially, according to the EU General Data
6
7 Protection Regulation and the Dutch Act on Implementation of the General Data Protection
8
9 Regulation. Unidentifiable data from this trial will be stored in data repositories from the
10
11 University of Groningen and Utrecht University.
12
13
14
15

16 Findings of this RCT will be disseminated among participants by means of a
17
18 newsletter. If shown to be effective, the treatment will be accessible for future bereaved
19
20 people because, as a result of this study, 1) a nationwide network of therapists are trained in
21
22 our protocol for the face-to-face treatment, and 2) because the online framework will be
23
24 made publicly accessible. Findings will also be disseminated among lay people by uploading
25
26 the newsletters on our website (www.rouwnaverkeersongeval.nl) and through media
27
28 performances. Our findings will be presented to our collaborators, including non-
29
30 governmental organizations and (peer-)support organizations for bereaved people.
31
32 Treatment materials are available online for free (see
33
34 www.rouwnaverkeersongeval.nl/downloads). Lastly, colleagues will be informed about our
35
36 findings during presentations at (inter)national conferences and by articles in scientific
37
38 journals.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

The relatively few RCTs among general bereaved people with elevated grief levels indicate that grief-specific CBT-based interventions delivered face-to-face or online yield the largest effects on post-loss mental health compared with a waiting list[21–24]. RCTs evaluating treatment effects for people with elevated mental health complaints after confrontation with sudden/violent losses are lacking, with one notable exception that compared EMDR plus CBT vs. wait list controls[30]. Given that traumatically bereaved people are most strongly at risk for PCBD and comorbid PTSD and depression[8], it seems particularly relevant to develop evidence-based interventions for this population.

This will be the first RCT to examine the effectiveness of CBT in a sample exclusively comprised of people exposed to a traumatic death. Furthermore, the effectiveness of face-to-face *and* online grief-specific CBT (vs. waitlist controls) will be examined for the first time in one trial. We are not able to test whether face-to-face and online CBT has equal effects. A non-inferiority trial would require a sample size of over 1000 people[62], which is not feasible given our resources. Nonetheless, the findings are expected to yield important insights in the effects of online CBT (vs. waitlist controls) relative to the effects of face-to-face CBT (vs. waitlist controls). Unlike prior studies, our study design enables a fair, albeit indirect comparison of face-to-face and online grief treatment. For instance, in this RCT the treatment conditions are designed to be as similar as possible in terms of treatment content, treatment duration, experience and training of therapists, outcome measures, and characteristics of study participants. When we find similar effect sizes for between group comparisons (face-to-face CBT vs. waiting list and online CBT vs. waiting list), CBT delivered online can be considered as supplement for or complementary to face-to-face treatment,

1
2
3 because it potentially overcomes drawbacks of face-to-face treatment, such as waiting lists
4
5 and travel expenses.
6
7

8
9 We will also examine potential mediators and moderators of change. Findings from
10
11 mediation analyses, examining the role of among others negative cognitions and avoidance
12
13 behaviors, will provide insights in potential underlying therapeutic processes to foster
14
15 recovery from traumatic loss. These insights are deemed important to design treatments
16
17 that more effectively target these mechanisms of change. Findings from the moderator
18
19 analyses are expected to improve our knowledge on for whom (e.g., women or people who
20
21 are more remotely bereaved) this grief-CBT works best. Findings on potential mediators and
22
23 moderators of change are necessary to improve treatments given that a maximum of 42% of
24
25 bereaved people report clinically relevant reductions in grief levels after treatment[21,23].
26
27
28
29

30
31 Lastly, the role of therapeutic alliance on therapy outcomes will be explored. Prior
32
33 research in bereaved people has shown that greater therapeutic alliance, from the
34
35 perspective of the client, at week 4 of a face-to-face grief-specific treatment, was related to
36
37 greater reductions in grief levels. This therapeutic alliance-grief relationship was not
38
39 significant for non-grief specific treatment[63]. Our exploration of this association, from the
40
41 perspective of client *and* therapist, may for the first time shed light on (similarities or
42
43 differences in) success rates of face-to-face and online CBT for traumatic grief.
44
45
46
47
48

49 An anticipated limitation of our RCT is the self-selected sample. It is possible that
50
51 people who are more open towards innovative technology in general[64] and received
52
53 support prior to the loss[35] are more likely to sign up for this study, limiting the
54
55 generalization of findings emerging from this study. Furthermore, we will use self-report
56
57 measures instead of diagnostic interviews, which may increase the risk of overestimating
58
59
60

1
2
3 symptom levels[65]. Another limitation of this trial may relate to the fact that the
4
5 operationalization and assessment of grief as a disorder is still under debate[66–68]. For
6
7 instance, PCBD, included as “condition for further study” in the DSM-5, is likely to be
8
9 changed in a revision of the DSM. To maximize diagnostic compatibility, we added four
10
11 items, corresponding to ICD-11 PGD criteria, to the TGI-SR, enabling operationalization of our
12
13 primary outcome measure in terms of diagnoses of pathological grief according to both
14
15 DSM-5 and ICD-11.
16
17
18
19
20

21 To conclude, this RCT will provide new insights in effectiveness of face-to-face and
22
23 online CBT for bereaved people after traffic accidents with clinically relevant distress as well
24
25 as in mediators and moderators of therapeutic change. As trials to date have primarily
26
27 focused on effects of face-to-face treatment for non-traumatically bereaved people, our
28
29 findings are expected to provide a valuable addition to the knowledge base on treating
30
31 severely distressed bereaved people.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 World Health Organization. The top 10 causes of death [Internet]. 2019 [accessed on
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
October 14 2019]. Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
- 2 Lundorff M, Holmgren H, Zachariae R, et al. Prevalence of prolonged grief disorder in adult bereavement: A systematic review and meta-analysis. *J Affect Disord.* 2017;212:138–49.
- 3 Onrust SA, Cuijpers P. Mood and anxiety disorders in widowhood: a systematic review. *Aging Ment Health.* 2006;10(4):327–34.
- 4 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013.
- 5 Boelen PA, van de Schoot R, van den Hout MA, et al. Prolonged Grief Disorder, depression, and posttraumatic stress disorder are distinguishable syndromes. *J Affect Disord.* 2010;125(1–3):374–8.
- 6 Lenferink LIM, Nickerson A, de Keijser J, et al. Trajectories of grief, depression, and posttraumatic stress in disaster-bereaved people. *Depress Anxiety.* 2018.
- 7 Malgaroli M, Maccallum F, Bonanno GA. Symptoms of persistent complex bereavement disorder, depression, and PTSD in a conjugally bereaved sample: a network analysis. *Psychol Med.* 2018;48(14):2439–48.

- 1
2
3 8 Heeke C, Kampisiou C, Niemeyer H, et al. A systematic review and meta-analysis of
4
5 correlates of prolonged grief disorder in adults exposed to violent loss. *Eur J*
6
7 *Psychotraumatology*. 2019;10(1).
8
9
10
11 9 Kristensen P, Weisæth L, Heir T. Bereavement and mental health after sudden and violent
12
13 losses: a review. *Psychiatry*. 2012;75(1):76–97.
14
15
16
17 10 Smid GE, Kleber RJ, Rie SM de la, et al. Brief Eclectic Psychotherapy for Traumatic Grief
18
19 (BEP-TG): toward integrated treatment of symptoms related to traumatic loss. *Eur J*
20
21 *Psychotraumatology*. 2015;6(1):27324.
22
23
24
25 11 Eisma, M.C., de Keijser, J. Nabestaanden van verkeersongevallen. In: de Keijser, J., Boelen,
26
27 P.A., Smid, G.E., redacteuren. Handboek traumatische rouw. Amsterdam: Uitgeverij
28
29 Boom; 2018. p. 104–16.
30
31
32
33 12 Boelen PA, de Keijser J, Smid G. Cognitive–behavioral variables mediate the impact of
34
35 violent loss on post-loss psychopathology. *Psychol Trauma Theory Res Pract Policy*.
36
37 2015;7(4):382–90.
38
39
40
41 13 Boelen PA, van den Hout MA, van den Bout J. A Cognitive-Behavioral Conceptualization of
42
43 Complicated Grief. *Clin Psychol Sci Pract*. 2006;13(2):109–28.
44
45
46
47 14 Janoff-Bulman R. Assumptive worlds and the stress of traumatic events: Applications of
48
49 the schema construct. *Soc Cogn*. 1989;7(2):113–36.
50
51
52
53 15 Boelen PA, Lensvelt-Mulders GJLM. Psychometric Properties of the Grief Cognitions
54
55 Questionnaire (GCQ). *J Psychopathol Behav Assess*. 2005;27(4):291–303.
56
57
58
59
60

- 1
2
3 16 Foa EB, Riggs DS, Massie ED, et al. The impact of fear activation and anger on the efficacy
4
5 of exposure treatment for posttraumatic stress disorder. *Behav Ther.* 1995;26(3):487–
6
7 99.
8
9
10
11 17 Tehrani N. Road victim trauma: an investigation of the impact on the injured and
12
13 bereaved. *Couns Psychol Q.* 2004;17(4):361–73.
14
15
16
17 18 Boelen PA. A Sense of ‘unrealness’ about the death of a loved-one: An exploratory study
18
19 of its role in emotional complications among bereaved individuals. *Appl Cogn Psychol.*
20
21 2010;24(2):238–51.
22
23
24
25 19 Boelen PA. “It feels as if she might return one day”: A sense of unrealness as a predictor
26
27 of bereavement-related emotional distress / “Tengo la sensación de que ella puede
28
29 volver algún día”: la sensación de irrealidad como un predictor del sufrimiento
30
31 emocional relacionado con la pérdida. *Estud Psicol.* 2017;38(3):734–51.
32
33
34
35
36 20 Benight CC. Social cognitive theory of posttraumatic recovery: the role of perceived self-
37
38 efficacy. *Behav Res Ther.* 2004;42(10):1129–48.
39
40
41
42 21 Boelen PA, Smid GE. Disturbed grief: prolonged grief disorder and persistent complex
43
44 bereavement disorder. *BMJ.* 2017;357:j2016.
45
46
47
48 22 Currier JM, Holland JM, Neimeyer RA. Do CBT-Based Interventions Alleviate Distress
49
50 Following Bereavement? A Review of the Current Evidence. *Int Cog Ther.* 2010;3:77.93.
51
52
53
54 23 Doering BK, Eisma MC. Treatment for complicated grief: state of the science and ways
55
56 forward. *Curr Opin Psychiatry.* 2016;29(5):286–91.
57
58
59
60

- 1
2
3 24 Johannsen M, Damholdt MF, Zachariae R, et al. Psychological interventions for grief in
4
5 adults: A systematic review and meta-analysis of randomized controlled trials. *J Affect*
6
7 *Disord.* 2019;253:69–86.
8
9
10
11 25 Boelen PA, Keijser J de, Hout MA van den, et al. Factors associated with outcome of
12
13 cognitive–behavioural therapy for complicated grief: A preliminary study. *Clin Psychol*
14
15 *Psychother.* 2011;18(4):284–91.
16
17
18
19 26 Bryant RA, Kenny L, Joscelyne A, et al. Predictors of treatment response for cognitive
20
21 behaviour therapy for prolonged grief disorder. *Eur J Psychotraumatology.* 2019;8(6).
22
23
24
25 27 Linde K, Trembl J, Steinig J, et al. Grief interventions for people bereaved by suicide: A
26
27 systematic review. *PloS One.* 2017;12(6):e0179496.
28
29
30
31 28 Wittouck C, Van Autreve S, De Jaegere E, et al. The prevention and treatment of
32
33 complicated grief: a meta-analysis. *Clin Psychol Rev.* 2011;31(1):69–78.
34
35
36
37 29 de Heus A, Hengst SMC, de la Rie SM, et al. Day patient treatment for traumatic grief:
38
39 preliminary evaluation of a one-year treatment programme for patients with multiple
40
41 and traumatic losses. *Eur J Psychotraumatology.* 2017;8(1).
42
43
44
45 30 van Denderen M, de Keijser J, Stewart R, et al. Treating complicated grief and
46
47 posttraumatic stress in homicidally bereaved individuals: A randomized controlled trial.
48
49 *Clin Psychol Psychother.* 2018.
50
51
52
53 31 Eisma MC, Boelen PA, van den Bout J, et al. Internet-Based Exposure and Behavioral
54
55 Activation for Complicated Grief and Rumination: A Randomized Controlled Trial. *Behav*
56
57 *Ther.* 2015;46(6):729–48.
58
59
60

- 1
2
3 32 Kersting A, Dölemeyer R, Steinig J, et al. Brief Internet-based intervention reduces
4
5 posttraumatic stress and prolonged grief in parents after the loss of a child during
6
7 pregnancy: a randomized controlled trial. *Psychother Psychosom.* 2013;82(6):372–81.
8
9
10
11 33 Wagner B, Knaevelsrud C, Maercker A. Internet-based cognitive-behavioral therapy for
12
13 complicated grief: a randomized controlled trial. *Death Stud.* 2006;30(5):429–53.
14
15
16
17 34 Baumeister H, Reichler L, Munzinger M, et al. The impact of guidance on Internet-based
18
19 mental health interventions — A systematic review. *Internet Interv.* 2014;1(4):205–15.
20
21
22
23 35 Lichtenthal WG, Corner GW, Sweeney CR, et al. Mental Health Services for Parents Who
24
25 Lost a Child to Cancer: If We Build Them, Will They Come? *J Clin Oncol Off J Am Soc Clin*
26
27 *Oncol.* 2015;33(20):2246–53.
28
29
30
31 36 Andersson G, Titov N. Advantages and limitations of Internet-based interventions for
32
33 common mental disorders. *World Psychiatry.* 2014;13(1):4–11.
34
35
36
37 37 Melville KM, Casey LM, Kavanagh DJ. Dropout from Internet-based treatment for
38
39 psychological disorders. *Br J Clin Psychol.* 2010;49(Pt 4):455–71.
40
41
42
43 38 Pihlaja S, Stenberg J-H, Joutsenniemi K, et al. Therapeutic alliance in guided internet
44
45 therapy programs for depression and anxiety disorders - A systematic review. *Internet*
46
47 *Interv.* 2018;11:1–10.
48
49
50
51 39 Bordin ES. Theory and research on the therapeutic working alliance: New directions. In:
52
53 The working alliance: Theory, research, and practice. Oxford, England: John Wiley &
54
55 Sons; 1994. p. 13–37.
56
57
58
59
60

- 1
2
3 40 Cook JE, Doyle C. Working alliance in online therapy as compared to face-to-face therapy:
4 preliminary results. *Cyberpsychology Behav Impact Internet Multimed Virtual Real*
5
6 *Behav Soc.* 2002;5(2):95–105.
7
8
9
10
11 41 Sucala M, Schnur JB, Constantino MJ, et al. The therapeutic relationship in e-therapy for
12 mental health: a systematic review. *J Med Internet Res.* 2012;14(4):e110.
13
14
15
16
17 42 Lenferink LIM, de Keijser J, Wessel I, et al. Cognitive behavioural therapy and mindfulness
18 for relatives of missing persons: a pilot study. *Pilot Feasibility Stud.* 2019;5(1):93.
19
20
21
22
23 43 Boelen PA, Bout J van den. Protocollaire behandeling van persisterende complexe
24 rouwstoornis. In: Keijsers, G., Minnen, A. van, Verbraak, M., Hoogduin, K., Emmelkamp,
25 P., (Red.). Protocollaire behandelingen voor volwassenen met psychische klachten. Ed.
26
27 1. Amsterdam: Boom; 2017.
28
29
30
31
32
33
34 44 Boelen PA, Smid GE. The Traumatic Grief Inventory Self-Report Version (TGI-SR):
35 Introduction and Preliminary Psychometric Evaluation. *J Loss Trauma.* 2017;22(3):196–
36
37 212.
38
39
40
41
42 45 World Health Organization. ICD-11. Prolonged Grief Disorder Criteria [Internet]. 2018
43 [Accessed on October 14 2019]. Available from: [https://icd.who.int/browse11/l-](https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1183832314)
44
45 [m/en#/http://id.who.int/icd/entity/1183832314](https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1183832314)
46
47
48
49
50 46 Boelen PA, Djelantik AAAMJ, de Keijser J, et al. Further validation of the Traumatic Grief
51 Inventory-Self Report (TGI-SR): A measure of persistent complex bereavement disorder
52 and prolonged grief disorder. *Death Stud.* 2019;43(6):351–64.
53
54
55
56
57
58
59
60

- 1
2
3 47 Blevins CA, Weathers FW, Davis MT, et al. The Posttraumatic Stress Disorder Checklist for
4
5 DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. *J Trauma Stress*.
6
7 2015;28(6):489–98.
8
9
10
11 48 Boeschoten, M.A., Bakker, A., Jongedijk, et al. PTSS checklist voor de DSM-5 (PCL-5).
12
13 Diemen: Arq Nationaal Psychotrauma Centrum; 2014.
14
15
16
17 49 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*.
18
19 1983;67(6):361–70.
20
21
22
23 50 Spinhoven PH, Ormel J, Sloekers PPA, et al. A validation study of the Hospital Anxiety and
24
25 Depression scale (HADS) in different groups of Dutch subjects. *Psychol Med*.
26
27 1997;27(2):363–70.
28
29
30
31 51 Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple
32
33 measure of impairment in functioning. *Br J Psychiatry J Ment Sci*. 2002;180:461–4.
34
35
36
37 52 de Graaf LE, Gerhards SH, Arntz A, et al. Clinical effectiveness of online computerised
38
39 cognitive-behavioural therapy without support for depression in primary care:
40
41 randomised trial. *Br J Psychiatry J Ment Sci*. 2009;195(1):73–80.
42
43
44
45 53 Boelen PA, van den Bout J. Anxious and depressive avoidance and symptoms of
46
47 prolonged grief, depression, and post-traumatic stress disorder. *Psychol Belg*.
48
49 2010;50(1–2):49–67.
50
51
52
53 54 Spielberger, C.D. State-Trait Anger Expression Inventory-2. Psychological Assessment
54
55 Resources; 1999.
56
57
58
59
60

- 1
2
3 55 Lievaart M, Franken IHA, Hovens JE. Anger Assessment in Clinical and Nonclinical
4
5 Populations: Further Validation of the State-Trait Anger Expression Inventory-2. *J Clin*
6
7 *Psychol.* 2016;72(3):263–78.
8
9
10
11 56 Schwarzer, R., Jerusalem, M. Generalized self-efficacy scale. In: Weinman, J., Wright, S.,
12
13 Johnston, M., redacteurs. Measures in health psychology: A user's portfolio Causal
14
15 and control beliefs. Windsor, UK: Nfer-Nelson; 1995. p. 35–7.
16
17
18
19 57 Horvath AO, Greenberg LS. Development and validation of the Working Alliance
20
21 Inventory. *J Couns Psychol.* 1989;36(2):223–33.
22
23
24
25 58 Vertommen, H., Vervaeke, G. Nederlandstalige experimentele vertaling van de Working
26
27 Alliance Inventory van Horvath en Greenberg. Leuven: KU; 1990.
28
29
30
31 59 Munder T, Wilmers F, Leonhart R, et al. Working Alliance Inventory-Short Revised (WAI-
32
33 SR): psychometric properties in outpatients and inpatients. *Clin Psychol Psychother.*
34
35 2010;17(3):231–9.
36
37
38
39 60 Snijders, T.A.B., Bosker, R.J. Deviance tests. In: Snijders, T.A.B., Bosker, R.J., (Red.).
40
41 Multilevel analysis. London: SAGE Publications Ltd; 2012. p. 97–8.
42
43
44
45 61 Little, T. Mediation and moderation. In: Little, T., (Red.). Longitudinal Structural Equation
46
47 Modeling. New York: The Guilford Press; 2013. p. 286–324.
48
49
50
51 62 Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. *Trials.*
52
53 2011;12:106.
54
55
56
57 63 Glickman K, Shear KM, Wall MM. Therapeutic Alliance and Outcome in Complicated Grief
58
59 Treatment. *Int J Cogn Ther.* 2018;11(2):222–33.
60

1
2
3 64 Arjadi R, Nauta MH, Bockting CLH. Acceptability of internet-based interventions for
4
5 depression in Indonesia. *Internet Interv.* 2018;13:8–15.
6
7

8
9 65 Lim GY, Tam WW, Lu Y, et al. Prevalence of Depression in the Community from 30
10
11 Countries between 1994 and 2014. *Sci Rep.* 2018;8(1):2861.
12
13

14
15 66 Lenferink, L.I.M., Boelen, P.A., Smid, G.E., et al. The importance of harmonising diagnostic
16
17 criteria sets for pathological grief. *British Journal of Psychiatry.* in press;
18
19

20
21 67 Maciejewski PK, Prigerson HG. Prolonged, but not complicated, grief is a mental disorder.
22
23 *Br J Psychiatry.* 2017;211(4):189–91.
24
25

26
27 68 Wakefield JC. Should prolonged grief be reclassified as a mental disorder in DSM-5?:
28
29 reconsidering the empirical and conceptual arguments for complicated grief disorder. *J*
30
31 *Nerv Ment Dis.* 2012;200(6):499–511.
32
33

34 35 36 37 **Authors' contributions**

38
39 JdK, LL, and PB are the principal investigators. LL is the executive researcher. JdK, PB, ME,
40
41 and GS are the grant holders. LL developed the study design and wrote the ethics proposal
42
43 and drafts of the manuscript. JdK, ME, GS, and PB read, revised, and approved the drafts of
44
45 the study design, ethics proposal, and the manuscript.
46
47
48
49

50 51 **Funding statement**

52
53 Fund Victim Support subsidized this work. This funder does not have ultimate authority over
54
55 any of the research activities.
56
57

58 59 **Competing Interests Statement**

60

1
2
3 All authors declare to have no competing interests.
4
5

6 **Patient and Public Involvement**
7

8
9 A committee of representatives of bereaved people, non-governmental support
10 organizations, and professionals working with bereaved people is initiated for this project.
11
12

13
14 These committee members are involved in recruitment of participants, pilot-testing research
15 materials, and dissemination of findings.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	32

1	Roles and	#5a	Names, affiliations, and roles of protocol contributors	32
2	responsibilities:			
3	contributorship			
4				
5				
6	Roles and	#5b	Name and contact information for the trial sponsor	n/a
7	responsibilities:			
8	sponsor contact			
9	information			
10				
11				
12				
13	Roles and	#5c	Role of study sponsor and funders, if any, in study	32
14	responsibilities:		design; collection, management, analysis, and	
15	sponsor and funder		interpretation of data; writing of the report; and the	
16			decision to submit the report for publication, including	
17			whether they will have ultimate authority over any of	
18			these activities	
19				
20				
21				
22				
23	Roles and	#5d	Composition, roles, and responsibilities of the	n/a
24	responsibilities:		coordinating centre, steering committee, endpoint	
25	committees		adjudication committee, data management team, and	
26			other individuals or groups overseeing the trial, if	
27			applicable (see Item 21a for data monitoring committee)	
28				
29				
30				
31	Introduction			
32				
33	Background and	#6a	Description of research question and justification for	4-7
34	rationale		undertaking the trial, including summary of relevant	
35			studies (published and unpublished) examining benefits	
36			and harms for each intervention	
37				
38				
39				
40	Background and	#6b	Explanation for choice of comparators	4-7
41	rationale: choice of			
42	comparators			
43				
44				
45	Objectives	#7	Specific objectives or hypotheses	8
46				
47				
48	Trial design	#8	Description of trial design including type of trial (eg,	10
49			parallel group, crossover, factorial, single group),	
50			allocation ratio, and framework (eg, superiority,	
51			equivalence, non-inferiority, exploratory)	
52				
53				
54				

**Methods:
Participants,**

interventions, and outcomes

1			
2			
3			
4	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
5			
6			
7			
8			
9			
10			
11	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
12			
13			
14			
15			
16			
17	Interventions:		
18	description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
19			
20			
21			
22			
23	Interventions:		
24	modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
25			
26			
27			
28			
29			
30	Interventions:		
31	adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
32			
33			
34			
35	Interventions:		
36	concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
37			
38			
39	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
51			
52			
53			
54			
55			
56			
57	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including
58			
59			
60			

clinical and statistical assumptions supporting any sample size calculations

Recruitment [#15](#) Strategies for achieving adequate participant enrolment to reach target sample size 11-12

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation [#16a](#) Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 10

Allocation concealment mechanism [#16b](#) Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 10

Allocation: implementation [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 10

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 10

Blinding (masking): emergency unblinding [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial n/a

Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate 15-18

measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

1			
2			
3			
4			
5			
6			
7			
8			
9	Data collection plan:	#18b	
10	retention	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
11			
12			
13			
14			
15	Data management	#19	
16		Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	20
17			
18			
19			
20			
21			
22			
23	Statistics: outcomes	#20a	
24		Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	18-19
25			
26			
27			
28			
29			
30	Statistics: additional analyses	#20b	
31		Methods for any additional analyses (eg, subgroup and adjusted analyses)	18-19
32			
33			
34	Statistics: analysis population and missing data	#20c	
35		Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	18-19
36			
37			
38			
39			
40			
41	Methods: Monitoring		
42			
43	Data monitoring: formal committee	#21a	
44		Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	20
45			
46			
47			
48			
49			
50			
51			
52			
53			
54	Data monitoring: interim analysis	#21b	
55		Description of any interim analyses and stopping guidelines, including who will have access to these	20
56			
57			
58			
59			
60			

interim results and make the final decision to terminate the trial

1			
2			
3			
4	Harms	#22	Plans for collecting, assessing, reporting, and managing 20
5			solicited and spontaneously reported adverse events
6			and other unintended effects of trial interventions or trial
7			conduct
8			
9			
10			
11	Auditing	#23	Frequency and procedures for auditing trial conduct, if 20
12			any, and whether the process will be independent from
13			investigators and the sponsor
14			
15			
16	Ethics and		
17	dissemination		
18			
19			
20	Research ethics	#24	Plans for seeking research ethics committee / 20
21	approval		institutional review board (REC / IRB) approval
22			
23			
24	Protocol amendments	#25	Plans for communicating important protocol 20
25			modifications (eg, changes to eligibility criteria,
26			outcomes, analyses) to relevant parties (eg,
27			investigators, REC / IRBs, trial participants, trial
28			registries, journals, regulators)
29			
30			
31			
32	Consent or assent	#26a	Who will obtain informed consent or assent from 20
33			potential trial participants or authorised surrogates, and
34			how (see Item 32)
35			
36			
37	Consent or assent:	#26b	Additional consent provisions for collection and use of n/a
38	ancillary studies		participant data and biological specimens in ancillary
39			studies, if applicable
40			
41			
42			
43	Confidentiality	#27	How personal information about potential and enrolled 20
44			participants will be collected, shared, and maintained in
45			order to protect confidentiality before, during, and after
46			the trial
47			
48			
49	Declaration of	#28	Financial and other competing interests for principal 32
50	interests		investigators for the overall trial and each study site
51			
52			
53	Data access	#29	Statement of who will have access to the final trial 20
54			dataset, and disclosure of contractual agreements that
55			limit such access for investigators
56			
57			
58			
59			
60			

1	Ancillary and post trial	#30	Provisions, if any, for ancillary and post-trial care, and for	20
2	care		compensation to those who suffer harm from trial	
3			participation	
4				
5				
6	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	19-20
7	trial results		results to participants, healthcare professionals, the	
8			public, and other relevant groups (eg, via publication,	
9			reporting in results databases, or other data sharing	
10			arrangements), including any publication restrictions	
11				
12				
13				
14	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	n/a
15	authorship		professional writers	
16				
17				
18	Dissemination policy:	#31c	Plans, if any, for granting public access to the full	n/a
19	reproducible research		protocol, participant-level dataset, and statistical code	
20				
21				
22	Appendices			
23				
24	Informed consent	#32	Model consent form and other related documentation	n/a
25	materials		given to participants and authorised surrogates	
26				
27				
28	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	n/a
29			biological specimens for genetic or molecular analysis in	
30			the current trial and for future use in ancillary studies, if	
31			applicable	
32				
33				
34				

35 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
 36 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
 37 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Online cognitive behavioral therapy for traumatically bereaved people: Study protocol for a randomized waitlist-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035050.R1
Article Type:	Protocol
Date Submitted by the Author:	11-Jun-2020
Complete List of Authors:	Lenferink, Lonneke; Rijksuniversiteit Groningen, Clinical Psychology and Experimental Psychopathology; Utrecht University, Clinical Psychology de Keijser, Jos; Rijksuniversiteit Groningen, Clinical Psychology and Experimental Psychopathology Eisma, Maarten; Clinical Psychology and Experimental Psychopathology Boelen, Paul; Utrecht University, Clinical Psychology; Foundation Centrum '45 Smid, Geert; Foundation Centrum '45
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health, Evidence based practice
Keywords:	PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Online cognitive behavioral therapy for traumatically bereaved people: Study protocol for**
4
5 **a randomized waitlist-controlled trial**
6
7

8 Lenferink, L.I.M.*^{1,2}, de Keijser, J.¹, Eisma, M.C.¹, Smid, G.E.^{3,4,5}, & Boelen, P.A.^{2,3,4}
9
10

11
12 ¹ Department of Clinical Psychology and Experimental Psychopathology, Faculty of
13 Behavioral and Social Sciences, University of Groningen, Grote Kruisstraat 2/1, 9712 TS
14 Groningen, The Netherlands. E-mail L.I.M. Lenferink: l.i.m.lenferink@rug.nl.
15
16

17
18
19
20 ² Department of Clinical Psychology, Faculty of Social Sciences, Utrecht University, P.O. Box
21 80140, 3508 TC, Utrecht, The Netherlands.
22
23

24
25
26 ³ ARQ Nationaal Psychotrauma Centre, Nienoord 5, 1112 XE, Diemen, The Netherlands
27
28

29
30 ⁴ Foundation Centrum '45, Nienoord 5, 1112 XE Diemen, The Netherlands
31
32

33
34 ⁵ University of Humanistic Studies, Utrecht, The Netherlands
35

36 *Corresponding author
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

The traumatic death of a loved one, such as death due to a traffic accident, can precipitate persistent complex bereavement disorder (PCBD) and comorbid posttraumatic stress disorder (PTSD) and depression. Waitlist-controlled trials have shown that grief-specific cognitive behavioral therapy (CBT) is an effective treatment for such mental health problems. This is the first study that will examine the effectiveness of online CBT (vs. waitlist controls) in a sample exclusively comprised of people bereaved by a traumatic death. Our primary hypothesis is that people allocated to the online CBT condition will show larger reductions in PCBD, PTSD, and depression symptom levels at post-treatment than people allocated to a waitlist. We further expect that reductions in symptom levels during treatment are associated with reductions of negative cognitions and avoidance behaviors and the experience of fewer accident-related stressors. Moreover, the effect of the quality of the therapeutic alliance on treatment effects and drop-out rates will be explored.

Methods and analysis

A two-arm (online CBT vs. waiting list) open label parallel randomized controlled trial (RCT) will be conducted. Participants will complete questionnaires at pre-treatment and 12 and 20 weeks after study enrolment. Eligible for participation are Dutch adults who lost a loved one at least one year earlier due to a traffic accident and report clinically relevant levels of PCBD, PTSD, and/or depression. Multilevel modeling will be used.

Ethics and dissemination

1
2
3 Ethics approval has been received (METc UMCG: M20.252121). This study will provide new
4
5 insights in the effectiveness of online CBT for traumatically bereaved people. If the
6
7 treatment is demonstrated to be effective, it will be made publicly accessible. Findings will
8
9 be disseminated among lay people (e.g., through newsletters and media performances), our
10
11 collaborators (e.g., through presentations at support organizations), and clinicians and
12
13 researchers (e.g., through conference presentations and scientific journal articles).
14
15
16
17

18 **Strengths and limitations of this study**

- 21 • This study is the first to examine the effectiveness of online CBT (vs. waitlist controls)
22 in reducing psychopathology after traumatic loss in an RCT.
23
- 24 • This study is one of the first to examine potential correlates of change in symptom
25 levels following online treatment after traumatic loss.
26
- 27 • We are not able to formally test mediators or moderators of treatment effects.
28
- 29 • We are not able to examine if online CBT has equal effects as face-to-face CBT.
30
- 31 • We are not able to establish formal diagnoses, as we use self-report questionnaires,
32 instead of diagnostic interviews, to assess symptom levels.
33
34
35
36
37
38
39
40
41

42 **Trial registration number:** NL7497 (Dutch Trial Register)

43 **Word Count:** 5,133 words including main text
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Worldwide, traffic accidents represent the leading cause of unnatural deaths(1). Ten to 20 percent of bereaved people who experience natural deaths (e.g., illness) develop severe and persistent grief-related distress, including persistent complex bereavement disorder (PCBD), posttraumatic stress disorder (PTSD), and depression(2,3). Notably, PCBD has been introduced as other specified trauma- and stressor-related disorder, in the latest version of the Diagnostic and Statistical manual of Mental Diseases (DSM-5)(4). PCBD can be diagnosed if, after the death of a significant other at least 12 months earlier, a person experiences persistent yearning for the deceased and symptoms of reactive distress (e.g., emotional numbness) and social/identity disruption (e.g., feeling alone) causing impairment in daily life. While some PCBD symptoms overlap with PTSD (e.g., anger) and depression symptoms (e.g., diminished interest in activities), several studies have shown that these three syndromes are distinct(5–7). Unexpected/violent losses of a significant other, also referred to as a traumatic losses, including deaths caused by traffic accidents, increase risks for the development of PCBD, PTSD, and depression(8,9).

Heightened risk for developing psychopathology after deaths due to traffic accident

Specific circumstances of losses caused by accidents may account for the elevated risk of grief-related distress. For instance, experiencing multiple losses simultaneously, being a witness to the accident, and juridical and financial consequences are proposed to exacerbate grief-related distress(10). Furthermore, negative cognitions and avoidance behaviors may mediate the influence of sudden/violent loss on grief, PTSD, and depression levels(11). According to a cognitive-behavioral model three interacting malleable processes underlie disturbed grief reactions: i) negative cognitions, ii) avoidance behavior, and iii) difficulties integrating the loss into the autobiographical knowledge base(12).

1
2
3 Experiencing a loss due to a traffic accident may violate basic assumptions about the
4 world being a safe place(13). This may fuel negative cognitions (e.g., “I’m less worthy, since
5 s/he died” and “The death of him/her has taught me that the world is unjust) that may
6 exacerbate and maintain acute grief responses(14). Avoidance behaviors include depressive
7 avoidance and anxious avoidance strategies. Depressive avoidance refers to withdrawal from
8 social and occupational activities that were perceived as fulfilling before the death, out of
9 the conviction that these activities are no longer meaningful. Anxious avoidance strategies
10 serve to prevent confrontation with the reality of the death, out of fear that confrontation is
11 too painful(12). One potential way to avoid confrontation with the reality of the loss, is to
12 focus on angry thoughts and feelings (e.g., “I was angry at the police, courts, or
13 administration, because they did not do their work well enough”)(15). This seems to be a
14 frequently used avoidant coping strategy in bereaved people after traffic accidents and is
15 strongly related to PTSD(16). Difficulty with integration of the loss into the autobiographical
16 knowledge base refers to the difficulties connecting factual knowledge that the loss is
17 irreversible with existing information about the self and the relationship with the lost
18 person, stored in autobiographical memory. Memories related to the loss may lack context
19 in terms of time and place, causing the loss to be experienced as unreal(17). It has been
20 argued that this “sense of unrealness” may trigger intrusive memories and increase feelings
21 of numbness or shock once the bereaved person is confronted with reminders of the
22 loss(17,18). The extent to which a person believes that one is capable of managing stressor-
23 related thoughts, emotions, and behaviors, also referred to as self-efficacy (e.g., “I can
24 usually handle whatever comes my way”), has also been determined as an important factor
25 facilitating coping with traumatic stressors(19). Decreased self-efficacy, negative cognitions
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and insufficient integration of the loss may contribute to increased sensitivity to loss
4
5 reminders or secondary stressors following traumatic loss(20).
6
7

8 9 *Cognitive-behavioral therapy for grief-related distress*

10
11 Grief-specific CBT has been demonstrated to be the most effective treatment for bereaved
12
13 people with elevated grief levels(21–24). CBT targets the abovementioned cognitive-
14
15 behavioral variables with cognitive restructuring, loss-related exposure, and behavioral
16
17 activation. Notably, research on putative mechanisms of change of grief-specific CBT is
18
19 sparse(23) (but see(25,26)). Examining the effectiveness of grief-specific CBT and its
20
21 potential mechanisms of change in traumatically bereaved people with traumatic grief is
22
23 clinically relevant because it would enable tailoring of interventions to the specific needs of
24
25 this group, which could improve treatment outcomes(27).
26
27
28
29
30
31

32
33 Whilst the majority of trials assess the efficacy of face-to-face CBT(24), so far, to the
34
35 best of our knowledge, three online CBT-based interventions have been developed for
36
37 distressed bereaved people(28–30). These prior studies provided preliminary data on the
38
39 potential effectiveness of online grief-specific CBT, but had some limitations. For instance,
40
41 treatment was solely provided to people who experienced perinatal loss (29) or included
42
43 relatively small samples (28). Comparability between these three studies is also limited,
44
45 because interventions differed in treatment content; different elements of CBT were
46
47 offered, for instance behavioral activation, exposure (28), or writing assignments (29,30).
48
49 Offering CBT via the internet has some potential advantages. It may lower the threshold for
50
51 seeking treatment, because it can be delivered independent of geographical location.
52
53 Furthermore, asynchronous communication may be used, allowing the client and therapist
54
55 can contact each other at any preferred time(31). This may counter barriers to mental health
56
57
58
59
60

1
2
3 service use, such as difficulties with finding help, transportation concerns, or difficulties
4
5 scheduling treatment sessions(32). In addition, online CBT could reduce treatment costs,
6
7 improving accessibility and dissemination of care for people in need of support(33).
8
9
10 Moreover, during times of a crisis, such as the COVID-19 pandemic, it seems more relevant
11
12 than ever to further examine the effectiveness of online CBT for distressed bereaved people,
13
14 as it will allow them to retain access to evidence-based care (34).
15
16

17
18 A potential downside to online CBT is the high dropout rate found in earlier
19
20 studies(33,35). It has been argued that a strong therapeutic alliance might support
21
22 adherence to online treatment and mediates treatment effects (36). Therapeutic alliance is
23
24 defined as a positive emotional bond between client and therapist, whereby both parties
25
26 agree on the tasks and goals of the treatment(37). The client-therapist relationship might
27
28 also explain why online treatments are more effective with therapist guidance than without
29
30 (31). Concerns have been raised that developing a therapeutic relationship might be more
31
32 difficult when non-verbal communication is absent(38). However, studies in non-bereaved
33
34 samples indicate that developing a strong therapeutic alliance is possible during online
35
36 treatment(33) and that therapeutic alliance is often related to online treatment
37
38 outcomes(39), but not always (33). More research is needed to further examine the
39
40 interrelations of the quality of client-therapist relationship, drop-out, and treatment
41
42 outcomes in online CBT.
43
44
45
46
47
48
49
50

51 *Study objectives*

52
53
54 Our first aim is to examine the effectiveness of online CBT (vs. a waiting list control
55
56 condition) in reducing symptom levels of PCBD, PTSD, and depression in people bereaved by
57
58 a traffic accident. We expect that participants assigned to the online CBT condition will show
59
60

1
2
3 larger reductions in symptom levels of PCBD, PTSD, and depression compared with waitlist
4
5 controls at post-treatment assessments (Hypothesis 1).
6
7

8
9 Our second aim is to explore correlates of change. Based on prior research and
10 theories(12,16,19), we expect that reductions in negative cognitions, avoidance behaviors,
11 state anger, a sense of unrealness, and improvement in self-efficacy are related to
12 reductions in PCBD, PTSD, and depression levels in online CBT (Hypothesis 2a). Additionally,
13 we aim to explore whether background characteristics (i.e., gender, age, and educational
14 level, kinship to the deceased, and time since loss) and accident-related stressors (i.e., single
15 vs. multiple loss, witnessing the accident, and status of legal trial) are related to treatment
16 effects (Hypothesis 2b). We have no specific expectations regarding these associations
17 because prior treatment studies in bereaved people showed inconsistent results(24,25,40).
18 However, based on clinical experience, we expect that accident-related stressors are
19 associated with treatment effects, such that multiple loss, witnessing the accident, and on-
20 going legal trial negatively impact treatment effects.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Our third aim is to explore the associations between quality of the therapeutic
40 alliance and drop-out rates and treatment outcomes. We expect that a stronger therapeutic
41 alliance is related to lower dropout rates and better treatment outcomes.
42
43
44
45
46

47 **Methods and analysis**

48 **Design**

49
50
51 A two-arm (online CBT vs. waiting list) multi-centre open label parallel RCT will be
52 conducted. Randomization will take place after the participant is screened for eligibility-
53 based inclusion criteria (described below). A random number generator (www.random.org)
54
55
56
57
58
59
60

1
2
3 will be used by a blinded independent researcher, to perform the blocking randomization
4
5 procedure. An allocation ratio of 1:1 will be applied.
6
7

8
9 Participants allocated to the online CBT condition receive treatment within one week
10
11 after allocation. All participants will be asked to fill in questionnaires (described below) at
12
13 baseline (T1), 12 weeks post-allocation (T2 for the intervention condition and T1a for waitlist
14
15 controls), and 20 weeks post-allocation (T3 for the intervention condition and T1b for
16
17 waitlist controls). For participants in the waiting list control group, at the end of the 20-week
18
19 waiting period after which they will receive online CBT, they will be asked to fill in T2 and T3
20
21 12 and 20 weeks after starting treatment, respectively (see Figure 1). A link to online
22
23 questionnaires will be sent to the participants by a non-blinded member of the research
24
25 team at each time-point. A waitlist control group (instead of a no treatment control group) is
26
27 chosen to increase the likelihood of continued study participation by guaranteeing that all
28
29 participants receive treatment. Furthermore, the inclusion of a waiting list control group
30
31 allows a treatment versus no treatment comparison, that will provide knowledge about the
32
33 effects of treatment relative to natural recovery from loss.
34
35
36
37
38
39
40

41 In line with prior treatment studies from our research group(40,41), the treatment is
42
43 guided by licensed and registered psychologists who are a member of our Traumatic Loss
44
45 Network (i.e., an informal national network of trauma and grief therapists that are involved
46
47 in research projects of our research group). In total six therapists (including authors PB and
48
49 JdK who are registered clinical psychologists) will guide the participants online; participants
50
51 will receive feedback from the same therapist each time. The therapists will receive a
52
53 training, provided by LL, PB, and JdK, on the use of the treatment protocol of this
54
55 intervention study. In preparation for the training, therapists read all treatment materials
56
57
58
59
60

1
2
3 and a selection of grief treatment literature. Instructions about the use of the online
4
5 treatment interface will be given by its developers. During a 5-hour face-to-face group
6
7 meeting the rationale of the online treatment will be explained and research procedures will
8
9 be discussed. In a 2-hour online video-meeting outstanding questions regarding the
10
11 treatment and the research project will be answered. Supervision (by telephone or mail) by
12
13 PB and JdK is possible on request, for instance when therapists encounter difficulties in
14
15 treatment. Therapists will be contacted by a member of the research team by phone or
16
17 email biweekly to monitor treatment progress and protocol adherence. Treatment costs will
18
19 be reimbursed.
20
21
22
23
24
25

26 ==Figure 1 about here==
27
28

29 **Participants**

30
31
32 This RCT is part of a larger on-going research project (the “TrafVic-project”) examining the
33
34 psychological impact of, and care after, the death of a loved one due to a traffic accident.
35
36 We expect to recruit the majority of the participants via a survey that started in December
37
38 2018 and included the following question: “In this study we would like to offer psychological
39
40 help to persons who experience emotional problems. May we approach you with more
41
42 information about this offer, if your answers to this questionnaire show that you experience
43
44 emotional problems?” Those who answered ‘yes’ will be sent a letter with information about
45
46 the intervention, the treatment study, and an informed consent form (see Supplementary
47
48 Materials). A Dutch website (www.rounnaverkeersongeval.nl) has been developed so that
49
50 potential participants can read information about the research and treatment. People who
51
52 are interested can also sign up for the study via this website. Recruitment for this RCT had
53
54 not started at the time of submission of this manuscript.
55
56
57
58
59
60

1
2
3 To be eligible for study participation, the person must 1) be a family member,
4 spouse, or friend of a person who died due to a traffic accident at least one year earlier, 2)
5 be ≥ 18 years of age, and 3) meet DSM-5 criteria for PCBD and/or PTSD and/or experience
6 clinically relevant depression, based on questionnaire scores (see below for more details).
7
8 People are excluded when they do not master the Dutch language or have no Internet
9 access.
10
11
12
13
14
15
16
17

18 **Sample size**

19
20
21 To test our primary hypothesis (Hypothesis 1), a test for each outcome separately (PCBD,
22 PTSD, and depression) will be conducted to assess the effects of online CBT vs. waitlist
23 controls. To find a difference between two groups (online CBT vs. waitlist controls) of at least
24 a medium effect size ($f = 0.25$; based on prior research(22,28,40)) with a power of 80%, an α
25 of 0.017 (corrected for multiple testing, i.e., $0.05/3$, as there are three primary outcome
26 measures (PCBD, PTSD, and depression)), and a strong association ($r = .50$) between the pre-
27 and post-assessment, a sample size of 23 per condition is sufficient. Taking into account an
28 average dropout rate of 19% (22), a total sample size of 55 (46+9) is required to test
29 Hypothesis 1.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Because our data are nested (repeated measures) (level 1) within individuals (level
46 2), and possibly within families sharing the same household (level 3), multi-level modeling
47 will be performed to test hypothesis 1. Conducting a power analysis within a multi-level
48 framework is not feasible for various reasons(42). Our power analysis is therefore based on a
49 repeated measures ANOVA.
50
51
52
53
54
55
56

57 **Intervention**

1
2
3 Online CBT will consist of eight one-on-one sessions, called lessons, offered within a
4
5 timeframe of 12 weeks. Eight sessions have shown to be sufficient to yield clinically relevant
6
7 effects in prior research(40). Following Dutch guidelines for grief-specific CBT(42), central
8
9 components of the treatment are exposure, cognitive restructuring, and behavioral
10
11 activation. In the first session, psychoeducation is offered, including information about
12
13 possible emotional reactions to the death of a loved one in a traffic accident and processes
14
15 that might foster or hamper recovery. A rationale for the CBT interventions is provided.
16
17
18
19
20

21 Then, session 2, 3, and 4 are focused on exposure; the circumstances and story of the
22
23 loss are presented in detail, and the participant is encouraged to confront stimuli that s/he
24
25 tends to avoid. Exposure is conducted by imaginary exposure assignments and by writing
26
27 assignment that have proven to be effective in prior research(30). These writing assignments
28
29 are focused on writing a detailed narrative of the loss and its circumstances.
30
31
32
33

34 The next sessions (5 and 6) focus on identifying and changing negative cognitions
35
36 that hamper adjustment (i.e., cognitive restructuring); specific attention is paid to cognitions
37
38 connected with responsibility/guilt and anger that may be experienced following the
39
40 accidental death(10). Cognitive restructuring assignments are provided to gain an alternative
41
42 perspective on negative thoughts about the self, life, the future, through 1) psycho-
43
44 education about common unhelpful thoughts, 2) identifying one's own unhelpful thoughts,
45
46 and 3) challenging these thoughts. Participants are instructed to undertake these three steps
47
48 by providing a daily description of i) an emotional moment/event, ii) their thoughts during
49
50 this event, iii) their feelings (and intensity of these feelings on a scale of 1 through 10), iv)
51
52 their behavior, v) evaluation of their thoughts), and vi) alternative helpful thoughts.
53
54
55
56
57
58
59
60

1
2
3 In session 7 and 8, participants are encouraged to re-engage in previously valued
4 social, recreational, and occupational activities in order to facilitate the process of
5 adjustment. Behavioral activation assignments are focused on writing about valued activities
6 and making plans to achieve valued goals. Session 8 is also focused on what the participant
7 has learned and how to deal with difficulties in the future.
8
9

10
11
12
13
14
15
16 All information and assignments are presented in an online framework, offered via a
17 secure website. Participants receive online written information that consists of
18 psychoeducation, information about treatment content and structure, and homework
19 assignments. As part of the online treatment, participants also listen to a video-therapist
20 verbally sharing parts of information that are also presented in text. The video-therapists are
21 two therapists from the Traumatic Loss Network; one male and one female and both middle-
22 aged. At the start of the treatment the video-therapists introduce themselves and the
23 participant is asked to select one of the video-therapists. The information shared by these
24 video-therapists are recorded in video-messages in which they read parts of the texts out
25 loud. Each participant therefore receives the same information from a video-therapist.
26 Direct contact with the video-therapist is not possible.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Participants receive weekly asynchronous written feedback from one online therapist
45 on each assignment that they complete online. As mentioned earlier, six online therapists
46 are trained to guide the participants. The online therapists are instructed to contact the
47 participant twice a week; once to encourage participants to log in and complete assignments
48 and once to provide feedback on assignments. In total, they spend 30 minutes per week on
49 reading assignments and providing feedback. Moreover, participants are encouraged to ask
50
51
52
53
54
55
56
57
58
59
60

1
2
3 a family member or friend to support them during treatment. This support figure is then
4
5 informed about the treatment through written information in an online framework.
6
7

8 9 **Measures**

10 11 *Primary outcome measures*

12
13
14
15 PCBD will be assessed with the Traumatic Grief Inventory-Self Report (TGI-SR)(43). The TGI-
16
17 SR consists of 18 items on a 5-point Likert scale ranging from 1 = never through 5 = always.
18
19 Four items tapping disturbed grief criteria according to the 11th edition of the International
20
21 Classification of Diseases were added(44). An example of an item is: "I found it difficult to
22
23 trust others". The instruction of the original questionnaire was altered from referring to "the
24
25 death of your loved one" to "the death of your loved one(s) due to a traffic accident".
26
27
28
29 Psychometric properties of the TGI-SR are adequate(43,45). Participants are considered to
30
31 meet criteria for DSM-5 PCBD(4) when they score at least 3 ("Sometimes") on at least 1
32
33 criterion B symptom (Item 1, item 2, item 3, and item 14), at least 6 criterion C symptoms
34
35 (item 4 up to 11, and item 15 up to 18), and the criterion D symptom (item 13).
36
37
38
39

40
41 PTSD will be assessed with the PTSD Checklist for DSM-5 (PCL-5)(46) (Dutch version:
42
43 (47)). Participants rate how often they were bothered by each symptom (e.g., "In the past
44
45 month, how much were you bothered by trouble remembering important parts of the
46
47 accident?") on 5-point Likert scales (0 = not at all and 4 = extremely). The instruction and the
48
49 items of the original questionnaire are altered from referring to the "stressful event" to the
50
51 "the death of your loved one(s) due to a traffic accident". The PCL-5 has shown to be reliable
52
53 and valid(46). Participants meet the criteria for DSM-5 PTSD(4) when they score at least 2
54
55 ("Moderately") on 1 criterion B item (items 1-5), 1 criterion C item (items 6-7), 2 criterion D
56
57 items (items 8-14), and 2 criterion E items (items 15-20).
58
59
60

1
2
3 Depression symptom levels are assessed with the depression subscale of the HADS-
4 D(48). The HADS-D consists of 7 items (e.g., “I still enjoy the thing I used to do”) rated on 4-
5 point scores ranging from 0 (e.g., “Hardly at all”) through 3 (e.g., “Definitely as much”). The
6 Dutch HADS-D is a reliable and valid screening tool for depression(49). A cut-off score of ≥ 8
7 is used as indicator for clinically relevant depression(48).
8
9

16 *Secondary outcome measures*

17
18
19 Negative grief-related cognitions are assessed with 18 items from the Grief
20 Cognitions Questionnaire (GCQ)(14). Participants are asked to rate their agreement with
21 each item (e.g., “Since [-] is dead, I feel less worthy”) on 6-point scales varying from 0 =
22 disagree strongly through 5 = agree strongly. The psychometric properties have been
23 positively evaluated in prior research(14).
24
25
26
27
28
29
30

31
32 Avoidance is measured with the Depressive and Anxious Avoidance in Prolonged
33 Grief Questionnaire (DAAPGQ)(50). The depressive avoidance subscale consists of 5 items
34 (e.g. ‘Since [-] is dead, I do much less of the things that I used to enjoy.’) and the anxious
35 avoidance subscale consists of 4 items (e.g., ‘I avoid to dwell on painful thoughts and
36 memories connected to his/her death.’). Participants answer each item on an 8-point scale
37 with 0 = not at all true for me, and 7 = completely true for me. The DAAPGQ has adequate
38 psychometric properties(50).
39
40
41
42
43
44
45
46
47
48

49
50 State anger is assessed with the 15-item state anger subscale of the State-Trait Anger
51 Expression Inventory-2 (STAXI-2)(51) (Dutch version:(52)). Participants are asked to rate on
52 4-point Likert scales (1 = not at all and 4 = extremely) how angry they feel right now (e.g., “I
53 feel annoyed”). The STAXI-2 is a valid and reliable measure to assess state anger(52).
54
55
56
57
58
59
60

1
2
3 A sense of unrealness is measured with the 5-item Experienced Unrealness Scale(17).
4
5 Participants are asked to rate their agreement with each item (e.g., “I still can hardly imagine
6
7 that [-] will never be here again”) on 8-point scales (0 = not at all true for me 7 = completely
8
9 true for me). This instrument demonstrated adequate psychometric properties(17).
10
11
12

13
14 Self-efficacy is assessed with the General Self-Efficacy Scale (GSES)(53). The GSES is a
15
16 10-item measure. Participants are asked to rate their agreement with each item (e.g., “I can
17
18 solve most problems if I invest the necessary effort.”) on a 4-point scale (1 = completely not
19
20 true, 4 = completely true). The GSES has shown excellent reliability and validity(53).
21
22
23

24
25 Quality of the therapeutic alliance is measured with the 12-item Work Alliance
26
27 Inventory-Short Form, Client Version and Therapist Version after session 4 (WAI-SF)(54)
28
29 (Dutch version:(55). The WAI-SF consists of 12 items (e.g., Client version: “We agree on what
30
31 is important for me to work on”, Therapist Version: “We are working towards mutually
32
33 agreed upon goals.”) that are rated on 5-point scales (1 = never and 5 = always). Higher total
34
35 scores indicate a higher quality of the therapeutic alliance as perceived by the participant
36
37 and therapist. The WAI-SF is a reliable and valid assessment tool(56).
38
39
40
41

42 *Other measures*

43
44

45
46 Background characteristics (i.e., gender, age, and educational level, kinship to the deceased,
47
48 and time since loss) and accident-related stressors (i.e., single vs. multiple loss, witnessed
49
50 the accident, and status of legal trial) will be assessed with single items.
51
52
53

54
55 Participants are allowed to receive other forms of psychosocial, instrumental or legal
56
57 support during participation in the trial. Using a single question we will assess whether the
58
59 participants received other forms of psychosocial professional support. The following
60

1
2
3 question will be used: “During the past 12 weeks/8 weeks (for T2 and T3, respectively) did
4 you receive additional psychological professional support from a psychologist, therapist or
5 psychiatrist other than the (online) therapist from the TrafVic-study?” We will also include
6 two dichotomous items (yes/no) at T1 to assess psychological support received prior to
7 participation in the study, namely: “Did you ever receive support from a psychologist,
8 therapist or psychiatrist, for your own emotional/mental problems, prior to the loss of your
9 loved one due to a traffic accident?” and “Did you ever receive support from a psychologist,
10 therapist or psychiatrist, for your own emotional/mental problems, related to the loss of
11 your loved one due to a traffic accident?”
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Statistical analyses**

30
31
32 To examine the differences in reductions of symptom levels of PCBD, PTSD, and depression
33 from pre- to post-treatment/waiting period between the conditions (online CBT vs. waitlist),
34 three independent multi-level models will be built (Hypothesis 1). Symptom levels of PCBD,
35 PTSD, and depression will consecutively be included as dependent variables and condition
36 (online CBT vs. waitlist controls), time, and time x condition (interaction term) as predictor
37 variables, taking into account that repeated observations (level 1) are nested within
38 individuals (level 2), and within households (level 3; if applicable). Additionally, relevant
39 background, loss-related variables, and use of co-interventions (yes/no) during participation
40 in our study, will be included in the analysis as covariates. Deviance tests will be used to
41 examine whether inclusion of these covariates improves model fit(57). Data of all
42 participants entering the study will be included in all analyses (i.e., intention-to-treat
43 analysis). Furthermore, percentages of people meeting diagnostic criteria for PCBD, PTSD,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and clinically relevant depression will be calculated for each measurement occasion and
4
5 percentages of people reporting reliable change scores for each outcome measure, using a
6
7 formula from Jacobson and Truax(58, p. 14), will be reported.
8
9

10
11 To examine to what extent symptom improvement after treatment is related to
12
13 improvement in possible correlates of change, residual gain scores will be calculated for all
14
15 outcome measures (i.e., PCBD, PTSD, and depression) and possible correlates of change (i.e.,
16
17 negative cognitions, avoidance behaviors, state anger, a sense of unrealness, and self-
18
19 efficacy). Following previous research (cf. (59)), residual gain scores will be calculated by
20
21 subtracting the standardized combined pre-treatment scores of both conditions (T1 data
22
23 from immediate treatment condition and T1b data from waitlist condition) multiplied by the
24
25 correlation coefficient between standardized combined pre-treatment scores and
26
27 standardized post-treatment (or follow-up) scores from standardized post-treatment (or
28
29 follow up) scores. To test hypothesis 2a, multiple regression analyses will be conducted to
30
31 examine the associations between residual gain scores of PCBD, PTSD, or depression and
32
33 residual gain scores of negative cognitions, avoidance behaviors, state anger, a sense of
34
35 unrealness, and self-efficacy.
36
37
38
39
40
41
42
43

44 To achieve research aim 2b, multiple regression analyses will be used to examine to
45
46 what extent residual gain scores of PCBD, PTSD, and depression varies as function of a)
47
48 background characteristics, including gender (male/female), age (in years), and educational
49
50 level (low/high), kinship to the deceased (child/spouse vs other), and time since loss (in
51
52 years) and b) accident-related stressors, including number of losses (single vs multiple),
53
54 witnessing the accident (yes/no), and status of legal trial (not applicable/on-
55
56
57
58
59
60

1
2
3 going/completed). Condition (intervention vs. waitlist controls) will be added as a covariate
4
5 to fulfill research aim 2a and 2b.
6
7

8
9 To achieve the third research aim, a) differences in therapeutic alliance scores will be
10
11 assessed between people who completed and dropped out of treatment and b) multiple
12
13 regression analyses will be used to examine to what extent symptom improvement in PCBD,
14
15 PTSD, and depression is related to therapeutic alliance (from both participant and therapist
16
17 perspectives).
18
19

20 21 22 **Ethics and dissemination** 23

24
25 This study has been approved by a local ethics committee (METc UMCG: ID number:
26
27 M20.252121). The study will be conducted according to the principles of the Declaration of
28
29 Helsinki (8th version, 2013) and in accordance with the Medical Research Involving Human
30
31 Subjects Act. Collected data will be handled confidentially, according to the EU General Data
32
33 Protection Regulation and the Dutch Act on Implementation of the General Data Protection
34
35 Regulation. Unidentifiable data from this trial will be stored in data repositories from the
36
37 University of Groningen and Utrecht University.
38
39
40

41
42
43 Findings of this RCT will be disseminated among participants by means of a
44
45 newsletter. If shown to be effective, the online framework will be made publicly accessible,
46
47 so that it can benefit other bereaved people. Findings will also be disseminated among lay
48
49 people by uploading the newsletters on our website (www.rouwnaverkeersongeval.nl) and
50
51 through media performances. Our findings will be presented to our collaborators, including
52
53 non-governmental organizations and (peer-)support organizations for bereaved people.
54
55 Treatment materials will also be made available upon request. Lastly, colleagues will be
56
57
58
59
60

1
2
3 informed about our findings during presentations at (inter)national conferences and
4
5 publications in scientific journals.
6
7

8
9 **Patient and public involvement**

10
11
12 No patient involvement.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Discussion

The relatively few RCTs among general bereaved people with elevated grief levels indicate that grief-specific CBT-based interventions yield the largest effects on post-loss mental health compared with a waiting list(21–24). RCTs evaluating face-to-face or online treatment effects for people with elevated mental health complaints after confrontation with sudden/violent losses are lacking, with the exception of two studies that compared face-to-face EMDR plus CBT against waitlist controls(40,59). Given that traumatically bereaved people are at risk for PCBD and comorbid PTSD and depression(8), it seems particularly relevant to develop evidence-based interventions for this population.

This will be the first RCT to examine the effectiveness of online CBT in a sample exclusively comprised of people who experienced a traumatic death. We are not able to test whether the online CBT has equal effects as face-to-face CBT. Nonetheless, the findings are expected to yield important insights in the effects of online CBT. In this RCT, the online treatment is designed to be as similar as possible to face-face CBT in terms of treatment content, treatment duration, and experience and training of therapists. When we find effect sizes for online CBT that are similar to effect sizes found in earlier studies for face-to-face CBT, delivering CBT online can be considered as supplement to face-to-face treatment, in particular when barriers to face-to-face treatments, such as waiting lists and travel expenses, are experienced.

We will also examine potential correlates of change. These analyses, examining the associations between reductions in symptoms levels and among others negative cognitions and avoidance behaviors, will provide insights in potential underlying therapeutic processes to foster recovery from traumatic loss. These insights are deemed important to design

1
2
3 treatments that more effectively target these correlates of change. We also expect to
4
5 improve our knowledge on for whom (e.g., women or people who are more remotely
6
7 bereaved) grief-specific CBT works best. Findings on these potential correlates of change are
8
9 necessary to improve treatments given that a maximum of 42% of bereaved people report
10
11 clinically relevant reductions in grief levels after treatment(21).
12
13
14
15

16
17 Lastly, the role of therapeutic alliance on therapy outcomes will be explored. Prior
18
19 research in bereaved people has shown that greater therapeutic alliance, from the
20
21 perspective of the client, at week 4 of a face-to-face grief-specific treatment, was related to
22
23 greater reductions in grief levels. This therapeutic alliance-grief relationship was not
24
25 significant for a non-grief specific treatment(60). Our exploration of this association, from
26
27 the perspective of client *and* therapist, may for the first time shed light on therapeutic
28
29 processes in online CBT for traumatic grief.
30
31
32
33

34
35 An anticipated limitation of our RCT is the self-selected sample. It is possible that
36
37 people who are more open towards innovative technology in general(61) and who received
38
39 support prior to the loss(32) are more likely to sign up for this study, limiting the
40
41 generalizability of findings emerging from this study. Due to the absence of an active control
42
43 group (e.g., face-to-face CBT) we are not able to test the effects of online CBT compared
44
45 with an alternative treatment. Furthermore, we will use self-report measures instead of
46
47 diagnostic interviews, which may increase the risk of overestimating symptom levels(62).
48
49

50
51 Another potential limitation of this trial relates to the fact that the operationalization and
52
53 assessment of grief as a disorder is still under debate(63–65). For instance, PCBD, included as
54
55 “condition for further study” in the DSM-5, is likely to be changed in a revision of the DSM.
56
57 To maximize diagnostic compatibility, we added four items, corresponding to ICD-11 PGD
58
59
60

1
2
3 criteria, to the TGI-SR, enabling operationalization of our primary outcome measure in terms
4
5 of diagnoses of pathological grief according to both the DSM-5 and the ICD-11.
6
7

8
9 To conclude, this RCT will provide new insights in effectiveness of online CBT for
10
11 people who experience clinically relevant distress after bereavement due to a traffic
12
13 accident, as well as in potential correlates of therapeutic change. As trials to date have
14
15 primarily focused on effects of face-to-face treatment for non-traumatically bereaved
16
17 people, our findings are expected to provide a valuable addition to the knowledge base on
18
19 treating severely distressed bereaved people.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization. The top 10 causes of death [Internet]. 2019 [geciteerd 14 oktober 2019]. Beschikbaar op: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
2. Lundorff M, Holmgren H, Zachariae R, Farver-Vestergaard I, O'Connor M. Prevalence of prolonged grief disorder in adult bereavement: A systematic review and meta-analysis. *J Affect Disord.* 2017;212:138–49.
3. Onrust SA, Cuijpers P. Mood and anxiety disorders in widowhood: a systematic review. *Aging Ment Health.* 2006;10(4):327–34.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013.
5. Boelen PA, van de Schoot R, van den Hout MA, de Keijser J, van den Bout J. Prolonged Grief Disorder, depression, and posttraumatic stress disorder are distinguishable syndromes. *J Affect Disord.* 2010;125(1–3):374–8.
6. Lenferink LIM, Nickerson A, de Keijser J, Smid GE, Boelen PA. Trajectories of grief, depression, and posttraumatic stress in disaster-bereaved people. *Depress Anxiety.* 2018;
7. Malgaroli M, Maccallum F, Bonanno GA. Symptoms of persistent complex bereavement disorder, depression, and PTSD in a conjugally bereaved sample: a network analysis. *Psychol Med.* 2018;48(14):2439–48.

- 1
2
3 8. Heeke C, Kampisiou C, Niemeyer H, Knaevelsrud C. A systematic review and meta-
4
5 analysis of correlates of prolonged grief disorder in adults exposed to violent loss. *Eur J*
6
7 *Psychotraumatology* [Internet]. 2019 [geciteerd 14 oktober 2019];10(1). Beschikbaar
8
9 op: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442112/>
10
11
12
- 13
14 9. Kristensen P, Weisæth L, Heir T. Bereavement and mental health after sudden and
15
16 violent losses: a review. *Psychiatry*. 2012;75(1):76–97.
17
18
- 19
20 10. Eisma, M.C., de Keijser, J. Nabestaanden van verkeersongevallen. In: de Keijser, J.,
21
22 Boelen, P.A., Smid, G.E., redacteuren. *Handboek traumatische rouw*. Amsterdam:
23
24 Uitgeverij Boom; 2018. p. 104–16.
25
26
- 27
28 11. Boelen PA, de Keijser J, Smid G. Cognitive–behavioral variables mediate the impact of
29
30 violent loss on post-loss psychopathology. *Psychol Trauma Theory Res Pract Policy*.
31
32 2015;7(4):382–90.
33
34
- 35
36 12. Boelen PA, van den Hout MA, van den Bout J. A Cognitive-Behavioral Conceptualization
37
38 of Complicated Grief. *Clin Psychol Sci Pract*. 2006;13(2):109–28.
39
40
- 41
42 13. Janoff-Bulman R. Assumptive worlds and the stress of traumatic events: Applications of
43
44 the schema construct. *Soc Cogn*. 1989;7(2):113–36.
45
46
- 47
48 14. Boelen PA, Lensvelt-Mulders GJLM. Psychometric Properties of the Grief Cognitions
49
50 Questionnaire (GCQ). *J Psychopathol Behav Assess*. 2005;27(4):291–303.
51
52
- 53
54 15. Foa EB, Riggs DS, Massie ED, Yarczower M. The impact of fear activation and anger on
55
56 the efficacy of exposure treatment for posttraumatic stress disorder. *Behav Ther*.
57
58 1995;26(3):487–99.
59
60

- 1
2
3 16. Tehrani, N. Road victim trauma: an investigation of the impact on the injured and
4
5 bereaved. *Couns Psychol Q.* 2004;17(4):361–73.
6
7
- 8
9 17. Boelen PA. A Sense of ‘unrealness’ about the death of a loved-one: An exploratory
10
11 study of its role in emotional complications among bereaved individuals. *Appl Cogn*
12
13 *Psychol.* 2010;24(2):238–51.
14
15
- 16
17 18. Boelen PA. “It feels as if she might return one day”: A sense of unrealness as a predictor
18
19 of bereavement-related emotional distress / “Tengo la sensación de que ella puede
20
21 volver algún día”: la sensación de irrealidad como un predictor del sufrimiento
22
23 emocional relacionado con la pérdida. *Estud Psicol.* 2017;38(3):734–51.
24
25
- 26
27 19. Benight CC. Social cognitive theory of posttraumatic recovery: the role of perceived
28
29 self-efficacy. *Behav Res Ther.* 2004;42(10):1129–48.
30
31
- 32
33 20. Smid GE, Kleber RJ, Rie SM de la, Bos JBA, Gersons BPR, Boelen PA. Brief Eclectic
34
35 Psychotherapy for Traumatic Grief (BEP-TG): toward integrated treatment of symptoms
36
37 related to traumatic loss. *Eur J Psychotraumatology.* 2015;6(1):27324.
38
39
- 40
41 21. Boelen PA, Smid GE. Disturbed grief: prolonged grief disorder and persistent complex
42
43 bereavement disorder. *BMJ.* 2017;357:j2016.
44
45
- 46
47 22. Currier JM, Holland JM, Neimeyer RA. Do CBT-Based Interventions Alleviate Distress
48
49 Following Bereavement? A Review of the Current Evidence. *International Journal of*
50
51 *Cognitive Therapy.* 2010;3:77–93.
52
53
- 54
55 23. Doering BK, Eisma MC. Treatment for complicated grief: state of the science and ways
56
57 forward. *Curr Opin Psychiatry.* 2016;29(5):286–91.
58
59
60

- 1
2
3 24. Johannsen M, Damholdt MF, Zachariae R, Lundorff M, Farver-Vestergaard I, O'Connor
4
5 M. Psychological interventions for grief in adults: A systematic review and meta-
6
7 analysis of randomized controlled trials. *J Affect Disord.* 2019;253:69–86.
8
9
- 10
11 25. Boelen PA, Keijser J de, Hout MA van den, Bout J van den. Factors associated with
12
13 outcome of cognitive-behavioural therapy for complicated grief: A preliminary study.
14
15 *Clin Psychol Psychother.* 2011;18(4):284–91.
16
17
- 18
19 26. Bryant RA, Kenny L, Joscelyne A, Rawson N, Maccallum F, Cahill C, e.a. Predictors of
20
21 treatment response for cognitive behaviour therapy for prolonged grief disorder. *Eur J*
22
23 *Psychotraumatology* [Internet]. 2019 [geciteerd 13 oktober 2019];8(6). Beschikbaar op:
24
25 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383610/>
26
27
- 28
29 27. Linde K, Treml J, Steinig J, Nagl M, Kersting A. Grief interventions for people bereaved
30
31 by suicide: A systematic review. *PloS One.* 2017;12(6):e0179496.
32
33
- 34
35 28. Eisma MC, Boelen PA, van den Bout J, Stroebe W, Schut HAW, Lancee J, e.a. Internet-
36
37 Based Exposure and Behavioral Activation for Complicated Grief and Rumination: A
38
39 Randomized Controlled Trial. *Behav Ther.* 2015;46(6):729–48.
40
41
- 42
43 29. Kersting A, Dölemeyer R, Steinig J, Walter F, Kroker K, Baust K, e.a. Brief Internet-based
44
45 intervention reduces posttraumatic stress and prolonged grief in parents after the loss
46
47 of a child during pregnancy: a randomized controlled trial. *Psychother Psychosom.*
48
49 2013;82(6):372–81.
50
51
- 52
53 30. Wagner B, Knaevelsrud C, Maercker A. Internet-based cognitive-behavioral therapy for
54
55 complicated grief: a randomized controlled trial. *Death Stud.* 2006;30(5):429–53.
56
57
58
59
60

- 1
2
3 31. Baumeister H, Reichler L, Munzinger M, Lin J. The impact of guidance on Internet-based
4
5 mental health interventions — A systematic review. *Internet Interv.* 2014;1(4):205–15.
6
7
- 8
9 32. Lichtenthal WG, Corner GW, Sweeney CR, Wiener L, Roberts KE, Baser RE, e.a. Mental
10
11 Health Services for Parents Who Lost a Child to Cancer: If We Build Them, Will They
12
13 Come? *J Clin Oncol Off J Am Soc Clin Oncol.* 2015;33(20):2246–53.
14
15
- 16
17 33. Andersson G, Titov N. Advantages and limitations of Internet-based interventions for
18
19 common mental disorders. *World Psychiatry.* 2014;13(1):4–11.
20
21
- 22
23 34. Eisma MC, Boelen PA, Lenferink LIM. Prolonged grief disorder following the Coronavirus
24
25 (COVID-19) pandemic. *Psychiatry Res.* 2020;288:113031.
26
27
- 28
29 35. Melville KM, Casey LM, Kavanagh DJ. Dropout from Internet-based treatment for
30
31 psychological disorders. *Br J Clin Psychol.* 2010;49(Pt 4):455–71.
32
33
- 34
35 36. Pihlaja S, Stenberg J-H, Joutsenniemi K, Mehik H, Ritola V, Joffe G. Therapeutic alliance
36
37 in guided internet therapy programs for depression and anxiety disorders - A
38
39 systematic review. *Internet Interv.* 2018;11:1–10.
40
41
- 42
43 37. Bordin ES. Theory and research on the therapeutic working alliance: New directions. In:
44
45 *The working alliance: Theory, research, and practice.* Oxford, England: John Wiley &
46
47 Sons; 1994. p. 13–37. (Wiley series on personality processes).
48
49
- 50
51 38. Cook JE, Doyle C. Working alliance in online therapy as compared to face-to-face
52
53 therapy: preliminary results. *Cyberpsychology Behav Impact Internet Multimed Virtual*
54
55 *Real Behav Soc.* 2002;5(2):95–105.
56
57
58
59
60

- 1
2
3 39. Sucala M, Schnur JB, Constantino MJ, Miller SJ, Brackman EH, Montgomery GH. The
4
5 therapeutic relationship in e-therapy for mental health: A systematic review. *J Med*
6
7 *Internet Res.* 2012;14(4):e110.
8
9
10
11 40. van Denderen M, de Keijser J, Stewart R, Boelen PA. Treating complicated grief and
12
13 posttraumatic stress in homicidally bereaved individuals: A randomized controlled trial.
14
15 *Clin Psychol Psychother.* 2018;
16
17
18
19 41. Lenferink LIM, de Keijser J, Wessel I, Boelen PA. Cognitive behavioural therapy and
20
21 mindfulness for relatives of missing persons: A pilot study. *Pilot Feasibility Stud.*
22
23 2019;5(1):93.
24
25
26
27 42. Boelen PA, Bout J van den. Protocollaire behandeling van persisterende complexe
28
29 rouwstoornis. In: Keijsers, G., Minnen, A. van, Verbraak, M., Hoogduin, K., Emmelkamp,
30
31 P., redacteuren. *Protocollaire behandelingen voor volwassenen met psychische*
32
33 *klachten.* 1ste dr. Amsterdam: Boom; 2017.
34
35
36
37
38 43. Boelen PA, Smid GE. The Traumatic Grief Inventory Self-Report Version (TGI-SR):
39
40 Introduction and Preliminary Psychometric Evaluation. *J Loss Trauma.* 2017;22(3):196–
41
42 212.
43
44
45
46 44. World Health Organization. ICD-11. Prolonged Grief Disorder Criteria [Internet]. 2018
47
48 [geciteerd 14 oktober 2019]. Beschikbaar op: <https://icd.who.int/browse11/l->
49
50 [m/en#/http://id.who.int/icd/entity/1183832314](https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1183832314)
51
52
53
54
55
56
57
58
59
60

- 1
2
3 45. Boelen PA, Djelantik AAAMJ, de Keijser J, Lenferink LIM, Smid GE. Further validation of
4
5 the Traumatic Grief Inventory-Self Report (TGI-SR): A measure of persistent complex
6
7 bereavement disorder and prolonged grief disorder. *Death Stud.* 2019;43(6):351–64.
8
9
10
11 46. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress
12
13 Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation.
14
15 *J Trauma Stress.* 2015;28(6):489–98.
16
17
18
19 47. Boeschoten, M.A., Bakker, A., Jongedijk, R.A., Olff, M. PTSS checklist voor de DSM-5
20
21 (PCL-5). Diemen: Arq Nationaal Psychotrauma Centrum; 2014.
22
23
24
25 48. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.*
26
27 1983;67(6):361–70.
28
29
30
31 49. Spinhoven PH, Ormel J, Sloekers PPA, Kempen GIJM. A validation study of the Hospital
32
33 Anxiety and Depression scale (HADS) in different groups of Dutch subjects. *Psychol*
34
35 *Med.* 1997;27(2):363–70.
36
37
38
39 50. Boelen PA, van den Bout J. Anxious and depressive avoidance and symptoms of
40
41 prolonged grief, depression, and post-traumatic stress disorder. *Psychol Belg.*
42
43 2010;50(1–2):49–67.
44
45
46
47 51. Spielberger, C.D. State-Trait Anger Expression Inventory-2. *Psychological Assessment*
48
49 *Resources;* 1999.
50
51
52
53 52. Lievaart M, Franken IHA, Hovens JE. Anger Assessment in Clinical and Nonclinical
54
55 Populations: Further Validation of the State-Trait Anger Expression Inventory-2. *J Clin*
56
57 *Psychol.* 2016;72(3):263–78.
58
59
60

- 1
2
3 53. Schwarzer, R., Jerusalem, M. Generalized self-efficacy scale. In: Weinman, J., Wright, S.,
4
5 Johnston, M., redacteurs. Measures in health psychology: A user's portfolio Causal
6
7 and control beliefs. Windsor, UK: Nfer-Nelson; 1995. p. 35–7.
8
9
10
11 54. Horvath AO, Greenberg LS. Development and validation of the Working Alliance
12
13 Inventory. *J Couns Psychol.* 1989;36(2):223–33.
14
15
16
17 55. Vertommen, H., Vervaeke, G. Nederlandstalige experimentele vertaling van de Working
18
19 Alliance Inventory van Horvath en Greenberg. Leuven: KU; 1990.
20
21
22
23 56. Munder T, Wilmers F, Leonhart R, Linster HW, Barth J. Working Alliance Inventory-Short
24
25 Revised (WAI-SR): psychometric properties in outpatients and inpatients. *Clin Psychol*
26
27 *Psychother.* 2010;17(3):231–9.
28
29
30
31 57. Snijders, T.A.B., Bosker, R.J. Deviance tests. In: Snijders, T.A.B., Bosker, R.J.,
32
33 redacteurs. Multilevel analysis. London: SAGE Publications Ltd; 2012. p. 97–8.
34
35
36
37 58. Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful
38
39 change in psychotherapy research. *J Consult Clin Psychol.* 1991;59(1):12–9.
40
41
42
43 59. Lenferink LIM, de Keijser J, Smid GE, Boelen PA. Cognitive therapy and EMDR for
44
45 reducing psychopathology in bereaved people after the MH17 plane crash: Findings
46
47 from a randomized controlled trial. *Traumatology.* 2020;
48
49
50
51 60. Glickman K, Shear, K.M., Wall MM. Therapeutic Alliance and Outcome in Complicated
52
53 Grief Treatment. *Int J Cogn Ther.* 2018;11(2):222–33.
54
55
56
57 61. Arjadi R, Nauta MH, Bockting CLH. Acceptability of internet-based interventions for
58
59 depression in Indonesia. *Internet Interv.* 2018;13:8–15.
60

- 1
2
3 62. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the
4
5 Community from 30 Countries between 1994 and 2014. *Sci Rep*. 2018;8(1):2861.
6
7
8
9 63. Lenferink, L.I.M., Boelen, P.A., Smid, G.E., Paap, M.C.S. The importance of harmonising
10
11 diagnostic criteria sets for pathological grief. *British Journal of Psychiatry*. in press;
12
13
14
15 64. Maciejewski PK, Prigerson HG. Prolonged, but not complicated, grief is a mental
16
17 disorder. *Br J Psychiatry*. 2017;211(4):189–91.
18
19
20
21 65. Wakefield JC. Should prolonged grief be reclassified as a mental disorder in DSM-5?:
22
23 reconsidering the empirical and conceptual arguments for complicated grief disorder. *J*
24
25 *Nerv Ment Dis*. 2012;200(6):499–511.
26
27
28
29
30
31
32
33

34 **Authors' contributions**

35
36 JdK is principal investigator. LL is executive researcher. JdK, PB, ME, and GS are grant
37
38 holders. LL developed the study design and wrote the ethics proposal and drafts of the
39
40 manuscript. JdK, ME, GS, and PB read, revised, and approved the drafts of the study design,
41
42 ethics proposal, and the manuscript.
43
44
45
46

47 **Funding statement**

48
49 Fund Victim Support subsidized this work.
50
51

52 **Competing Interests Statement**

53
54
55
56 All authors declare to have no competing interests.
57
58
59
60

1
2
3 **Figure caption/legend**
4

5 **Figure 1.** Design of RCT
6

7
8 *Note.* CBT = cognitive behavioral therapy
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Design of RCT

356x148mm (96 x 96 DPI)

Supplementary File

Information for participants

Subject: Participation in study on the treatment of grief after a traffic accident

Dear sir/madam,

We ask you to take part in a scientific study. This participation is voluntary. In order to take part we do need your permission. You receive this information because you filled in a questionnaire some time ago, mapping the emotional consequences of the death of a loved one due to a traffic accident. You have indicated that you may be interested in taking part in a follow-up study exploring the effects of a treatment to learn to cope better with the death of your loved one.

Before you decide whether you want to take part in this study, you receive an explanation of what the study entails. Read this information carefully and ask the researcher to explain if you have questions.

1. General Information

This study is conducted by the University of Groningen, Utrecht University and Stichting Centrum '45. The study is financed by the Fonds Slachtofferhulp (Victim Support Fund). The study consists of participation in an online psychological treatment. The treatment is provided by therapists in various practices across the Netherlands. The medical-ethical review committee of the Universitair Medisch Centrum Groningen (Academic Medical Centre Groningen) has approved this study.

2. Purpose of the study

Those left behind after a traffic accident often indicate that the help provided does not sufficiently connect to their experiences. Therefore a treatment has been developed that is specifically intended for the partner, relatives and friends of someone who died due to a traffic accident. You can discuss with the therapist how you are coping with the loss and what the consequences of this loss are in your life. The aim of the treatment is to cope better with the loss. The treatment is part of a scientific study. The purpose of the study is to explore whether treatment leads to a reduction in emotional problems for those who lost someone due to a traffic accident.

3. Background of the study

During the treatment cognitive behavioural therapy will be used. Previous research has shown that cognitive behavioural therapy is the most effective treatment for reducing emotional problems after the loss of a loved one due to a natural cause (for instance illness). Cognitive behavioural therapy is mainly applied during individual sessions with a therapist (face-to-face treatment). Research has shown that cognitive behavioural therapy, offered via the internet (online treatment), also seems to be suitable for reducing problems after a natural death. More research is needed to find out whether this online version of cognitive behavioural therapy is also suitable for those who lost someone due to a traffic accident. The purpose of this study is to find out whether online cognitive behavioural therapy is accompanied by a reduction of emotional problems after the death of a loved one due to a traffic accident.

The online treatment is provided individually and consists of eight modules which you go through in twelve weeks. You will then have online contact with a therapist who will guide you during the treatment. In the Netherlands, a network of therapists has been trained in the online treatment of people

1
2
3 who lost someone due to a traffic accident. The therapists work at several treatment centres. The online
4 treatment is offered by Therapieland. Therapieland is a provider of psychological care via the internet.
5
6

7 **4. What participation entails**

8 If you take part, this will take at least 20 weeks in total for you.
9

10 *Screening*

11 First we will determine whether you can take part. You will be asked to fill in a questionnaire. The
12 questionnaire contains questions about emotional problems you may experience in response to the
13 passing away of your loved one due to a traffic accident. Also, questions are asked about previous
14 psychological help you may have received. The questionnaire is used to get a picture of the degree to
15 which you experience emotional problems.
16

17 If your completed questionnaire shows that you experience relatively few emotional problems, you
18 cannot take part in the study. You also cannot take part in the study if you have no access to the internet.
19 If your answers show that the treatment offered is not suitable for you, an alternative treatment will be
20 looked for in consultation with you.
21

22 It is possible that you filled out a questionnaire on this topic before. As problems can change over time,
23 we ask you to fill in a questionnaire once more. In this way we get a picture of the problems you are
24 experiencing at the moment.
25

26 *Treatment*

27 In order to be able to determine the effect of the treatment, participants are assigned to one of two
28 groups. The first group will start with the online treatment as soon as possible after registration. The
29 second group will start with the online treatment after a waiting period of 20 weeks. By adding a waitlist
30 group it can be determined that a reduction of problems is actually the result of the treatment, and not
31 of the passage of time. Which group you are assigned to will be determined by drawing lots. You and
32 we do not have any influence on the draw. We will let you know when your treatment starts.
33
34
35

36 *Measurements*

37 Before the treatment can start, you will be asked to fill in a questionnaire. This questionnaire will focus
38 on the problems you experience. We map these in order to be able to determine whether the treatment
39 might help you.
40

41 The therapist who will guide your online treatment will be informed of the results of this questionnaire
42 beforehand. In order to determine to what extent the treatment helps you, we ask you to fill in a
43 questionnaire not only beforehand, but also once during the treatment, after the last treatment session,
44 and 8 weeks after the treatment. People assigned to the waiting group will be asked to fill in an additional
45 questionnaire after 12 weeks and 20 weeks of waiting. In this way it can be determined whether the
46 treatment has been effective and what the short and long term effects of the treatment are. The filling
47 in will take approximately 10 to 30 minutes per measurement.
48
49
50

51 **5. What is expected from you**

52 In order to ensure that the study runs smoothly it is important that you adhere to the following
53 agreements. These agreements are that you:
54

- 55 ● contact the researcher in case of problems (the contact details are listed at the end of the
56 information letter);
- 57 ● keep all appointments with your therapist;
- 58 ● fill in the questionnaires before and after the treatment.
59
60

Besides, it is important that you contact the researcher if:

- your contact information changes
- you no longer wish to take part in the study

6. Possible negative effects

During the treatment you will actively engage with your thoughts and feelings about the loss. It is possible that feelings such as grief or loss or fatigue may temporarily increase in intensity. Filling in the questionnaire can also evoke emotional responses. When your problems increase to a great extent, you can contact the researcher via the contact details listed at the end of this letter.

7. Possible advantages and disadvantages

It is important that you carefully weigh the possible advantages and disadvantages before you decide to take part. The treatment may reduce your emotional problems, but this is not certain. Your participation will contribute to more knowledge about the treatment of emotional problems after the death of a loved one due to a traffic accident.

Disadvantages of taking part in the study may be:

- possible worsening of problems due to taking part in the treatment;
- possible worsening of problems due to filling in the questionnaire.

Participation in the study also means that:

- the study will cost you time;
- you will have to adhere to certain agreements.

These issues have all been described in section 4, 5 and 6 above.

8. If you do not wish to participate or if you wish to stop participating in the study

You decide whether or not to take part in the study. Participation is voluntary. If you do take part, you can always change your mind and stop participating after all, during the study as well. You do not have to give a reason for stopping. You do have to report this to the researcher immediately. The data collected up to that point will be used for the study.

If there is new information about the study that is important to you, the researcher will let you know this. We will then ask you if you continue to participate.

9. End of the study

Your participation in the study will end when: you will have filled in the questionnaire 8 weeks after the end of the treatment; you make the choice to stop participating; the researcher considers it better for you to stop participating; the government or the reviewing medical-ethical committee decide to end the study. The entire study will end when all participants are done. After processing all the data, the researcher will inform you of the most important outcomes of the study by means of a newsletter. You can indicate whether you wish to receive this newsletter at the end of the questionnaire.

10. Use and storage of your data

For this study your personal data will be collected, used and stored. This concerns data such as your name, address, date of birth and data related to your health. The collection, use and storage of your data is necessary to be able to answer the questions asked in this study and to publish the results. We ask your permission for the use of your data.

Confidentiality of your data

In order to protect your privacy, your data will get a code. Your name and other data which can identify you directly will be left out from this. Data can only be traced to you with the key to the code. The key to the code will remain safely stored at the local research institution. The data sent to eventual other parties involved only contain the code, but not your name or other data with which you can be identified. In reports and publications on the study the data cannot be traced to you either.

Access to your data for checks

Some people may get access to all your data at the research location, including the data without code. This is necessary to be able to check whether the study has been done properly and reliably. People who will gain access to your data for checking purposes will be the researchers Lonneke Lenferink, a research assistant and Jos de Keijser, the committee monitoring the safety of the study and international supervising authorities. They will keep your data secret. We ask you to give your permission for this access.

Data retention period

Your data must be retained at the research location for 15 years. They are stored in order to be able to make new provisions related to this study in the course of this study.

Withdrawal of permission

You can always withdraw your permission for the use of your personal data again. The research data collected up to the moment you withdraw permission will still be used in the study.

Further information about your rights regarding data processing

For general information about your rights you can contact the person responsible for processing your personal data. For this study this is Lonneke Lenferink (University of Groningen). In case of questions or complaints regarding the processing of your personal data we recommend that you contact her.

11. Insurance for test subjects

An insurance has been taken out for everyone taking part in the study. The insurance covers damage from the study. You can report damage to the researchers.

12. Informing family doctor/GP

We do not share information about your participation in the study with your family doctor/GP.

13. Compensation for participation

1
2
3
4 Participation in the online treatment is free of charge.
5
6

7 **14. Do you have any questions?**

8
9 In case of general questions regarding the study you can contact the researcher assistant. If you have
10 complaints about the study, you can discuss this with the researchers or with your treating therapist. If
11 you prefer not to do this, you can contact the University of Groningen.
12
13

14 **15. Signing the consent form**

15
16 Below you find a 'Declaration of consent for participation in research into the treatment of grief after a
17 traffic accident', on which you can indicate whether you wish to take part in the study. With your
18 permission you indicate that you have understood the information and that you agree to participate in
19 the study.
20
21

22
23 After you have filled in this declaration, you can start filling in the questionnaire. Approximately within
24 four weeks after filling in the questionnaire we will let you know by email or by phone whether you
25 qualify for the treatment. When you qualify for treatment, you will receive the outcome of the draw
26 which indicates whether you have been assigned to a group that can start with the online treatment as
27 soon as possible, or whether you have been assigned to the group that needs to wait for 20 weeks before
28 the start of the online treatment.
29

30
31 If you have any further questions, you can contact us via the details below.
32

33 Kind regards,
34

35
36 [name research assistant]
37

38 Research assistant University of Groningen
39

40
41 Lonneke Lenferink
42

43
44 Post-doctoral researcher University of Groningen and Utrecht University
45
46
47

48 **Contact Details**

49
50 General questions about the study: [name research assistant], info@rouwnaverkeersongeval.nl
51

52
53 Questions regarding the protection of your data, your rights or complaints: please contact Lonneke
54 Lenferink, i.m.lenferink@rug.nl.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Consent Form
for participation in research on treatment of grief after a traffic accident

- I have read the information letter. I also had the opportunity to ask questions. My questions have been answered adequately. I had enough time to decide whether to participate or not.
- I know that participation is voluntary. I also know that I can decide at any moment not to participate after all or to stop participating in the study. I do not have to give a reason for this.
- I give permission for collecting and using my data to answer the research question of this study.
- I know that some people may gain access to all of my data for the purpose of checks of this study. Those people are listed in this information letter. I give permission for this access by these people.
- I wish to participate in this study.

Name of participant:

Email address:

Phone number:

Signature of participant:

Date: __ / __ / __

The researcher, Lonneke Lenferink, hereby declares that the test subject has been fully informed about the aforementioned study.

If information becomes known during the study which might influence the consent of the participant, the participant will be timely informed about this.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

			Page
	Reporting Item		Number
Administrative information			
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym		1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	3
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	n/a
7	data set		Registration Data Set	
8				
9				
10				
11				
12	Protocol version	#3	Date and version identifier	n/a
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	32
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	32
21	responsibilities:			
22				
23	contributorship			
24				
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	n/a
29	responsibilities:			
30				
31	sponsor contact			
32				
33	information			
34				
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	32
39	responsibilities:		design; collection, management, analysis, and	
40			interpretation of data; writing of the report; and the	
41	sponsor and funder		decision to submit the report for publication, including	
42			whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	n/a
53	responsibilities:		coordinating centre, steering committee, endpoint	
54			adjudication committee, data management team, and	
55	committees			
56				
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-7
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4-7
Objectives	#7	Specific objectives or hypotheses	8
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	8-9
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	10

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	11
2			applicable, eligibility criteria for study centres and	
3			individuals who will perform the interventions (eg,	
4			surgeons, psychotherapists)	
5				
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	12-13
12			replication, including how and when they will be	
13	description		administered	
14				
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	19
20			interventions for a given trial participant (eg, drug dose	
21	modifications		change in response to harms, participant request, or	
22			improving / worsening disease)	
23				
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	10
30			and any procedures for monitoring adherence (eg, drug	
31	adherence		tablet return; laboratory tests)	
32				
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	16-17
37			permitted or prohibited during the trial	
38	concomitant care			
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	14-17
43			specific measurement variable (eg, systolic blood	
44			pressure), analysis metric (eg, change from baseline, final	
45			value, time to event), method of aggregation (eg, median,	
46			proportion), and time point for each outcome. Explanation	
47			of the clinical relevance of chosen efficacy and harm	
48			outcomes is strongly recommended	
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including any	10
2			run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly recommended	
4			(see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	11
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any sample	
14			size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment to	10
22			reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	8-9
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document that	
41			is unavailable to those who enrol participants or assign	
42			interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	8-9
54	concealment		central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			
59				
60				

sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Allocation:	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a

**Methods: Data
collection,
management, and
analysis**

Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14-17
----------------------	----------------------	--	-------

1	Data collection plan:	#18b	Plans to promote participant retention and complete	n/a
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	19
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18				
19				
20				
21				
22				
23	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	17-20
24			outcomes. Reference to where other details of the	
25			statistical analysis plan can be found, if not in the protocol	
26				
27				
28				
29				
30				
31	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	17-20
32	analyses		adjusted analyses)	
33				
34				
35				
36	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	17-20
37	population and		adherence (eg, as randomised analysis), and any	
38	missing data		statistical methods to handle missing data (eg, multiple	
39			imputation)	
40				
41				
42				
43				
44				
45				
46	Methods: Monitoring			
47				
48				
49	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	19
50	formal committee		summary of its role and reporting structure; statement of	
51			whether it is independent from the sponsor and	
52			competing interests; and reference to where further	
53				
54				
55				
56				
57				
58				
59				
60				

1 details about its charter can be found, if not in the
 2
 3 protocol. Alternatively, an explanation of why a DMC is
 4
 5 not needed
 6
 7

8	Data monitoring:	#21b	Description of any interim analyses and stopping	19
9				
10	interim analysis		guidelines, including who will have access to these	
11				
12			interim results and make the final decision to terminate	
13				
14			the trial	
15				
16				
17				
18	Harms	#22	Plans for collecting, assessing, reporting, and managing	19
19				
20			solicited and spontaneously reported adverse events and	
21				
22			other unintended effects of trial interventions or trial	
23				
24			conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if	19
29				
30			any, and whether the process will be independent from	
31				
32			investigators and the sponsor	
33				
34				
35	Ethics and			
36				
37	dissemination			
38				
39				
40				
41	Research ethics	#24	Plans for seeking research ethics committee / institutional	19
42				
43	approval		review board (REC / IRB) approval	
44				
45				
46	Protocol	#25	Plans for communicating important protocol modifications	19
47				
48	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
49				
50			relevant parties (eg, investigators, REC / IRBs, trial	
51				
52			participants, trial registries, journals, regulators)	
53				
54				
55				
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential	19
2			trial participants or authorised surrogates, and how (see	
3			Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
10			participant data and biological specimens in ancillary	
11	ancillary studies		studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	19
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	32
27			investigators for the overall trial and each study site	
28	interests			
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	19
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	19
40			compensation to those who suffer harm from trial	
41	trial care		participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	19-20
48			results to participants, healthcare professionals, the	
49	trial results		public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1 Dissemination policy: [#31b](#) Authorship eligibility guidelines and any intended use of n/a
 2 authorship professional writers
 3
 4

5
 6 Dissemination policy: [#31c](#) Plans, if any, for granting public access to the full n/a
 7 reproducible protocol, participant-level dataset, and statistical code
 8
 9
 10
 11 research
 12

13 Appendices

14
 15
 16
 17 Informed consent [#32](#) Model consent form and other related documentation 10
 18 materials given to participants and authorised surrogates
 19
 20

21
 22
 23 Biological specimens [#33](#) Plans for collection, laboratory evaluation, and storage of n/a
 24 biological specimens for genetic or molecular analysis in
 25 the current trial and for future use in ancillary studies, if
 26
 27
 28
 29 applicable
 30
 31

32
 33 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
 34 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
 35 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Online cognitive behavioral therapy for traumatically bereaved people: Study protocol for a randomized waitlist-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035050.R2
Article Type:	Protocol
Date Submitted by the Author:	21-Jul-2020
Complete List of Authors:	Lenferink, Lonneke; Rijksuniversiteit Groningen, Clinical Psychology and Experimental Psychopathology; Utrecht University, Clinical Psychology de Keijser, Jos; Rijksuniversiteit Groningen, Clinical Psychology and Experimental Psychopathology Eisma, Maarten; Clinical Psychology and Experimental Psychopathology Smid, Geert; Foundation Centrum '45 Boelen, Paul; Utrecht University, Clinical Psychology; Foundation Centrum '45
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health, Evidence based practice
Keywords:	PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Online cognitive behavioral therapy for traumatically bereaved people: Study protocol for**
4
5 **a randomized waitlist-controlled trial**
6
7

8 Lenferink, L.I.M.*^{1,2}, de Keijser, J.¹, Eisma, M.C.¹, Smid, G.E.^{3,4,5}, & Boelen, P.A.^{2,3,4}
9
10

11
12 ¹ Department of Clinical Psychology and Experimental Psychopathology, Faculty of
13 Behavioral and Social Sciences, University of Groningen, Grote Kruisstraat 2/1, 9712 TS
14 Groningen, The Netherlands. E-mail L.I.M. Lenferink: l.i.m.lenferink@rug.nl.
15
16

17
18
19
20 ² Department of Clinical Psychology, Faculty of Social Sciences, Utrecht University, P.O. Box
21 80140, 3508 TC, Utrecht, The Netherlands.
22
23

24
25
26 ³ ARQ Nationaal Psychotrauma Centre, Nienoord 5, 1112 XE, Diemen, The Netherlands
27
28

29
30 ⁴ Foundation Centrum '45, Nienoord 5, 1112 XE Diemen, The Netherlands
31
32

33
34 ⁵ University of Humanistic Studies, Utrecht, The Netherlands
35

36 *Corresponding author
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

The traumatic death of a loved one, such as death due to a traffic accident, can precipitate persistent complex bereavement disorder (PCBD) and comorbid posttraumatic stress disorder (PTSD) and depression. Waitlist-controlled trials have shown that grief-specific cognitive behavioral therapy (CBT) is an effective treatment for such mental health problems. This is the first study that will examine the effectiveness of online CBT (vs. waitlist controls) in a sample exclusively comprised of people bereaved by a traumatic death. Our primary hypothesis is that people allocated to the online CBT condition will show larger reductions in PCBD, PTSD, and depression symptom levels at post-treatment than people allocated to a waitlist. We further expect that reductions in symptom levels during treatment are associated with reductions of negative cognitions and avoidance behaviors and the experience of fewer accident-related stressors. Moreover, the effect of the quality of the therapeutic alliance on treatment effects and drop-out rates will be explored.

Methods and analysis

A two-arm (online CBT vs. waiting list) open label parallel randomized controlled trial (RCT) will be conducted. Participants will complete questionnaires at pre-treatment and 12 and 20 weeks after study enrolment. Eligible for participation are Dutch adults who lost a loved one at least one year earlier due to a traffic accident and report clinically relevant levels of PCBD, PTSD, and/or depression. Multilevel modeling will be used.

Ethics and dissemination

1
2
3 Ethics approval has been received by the Medical Ethics Review Board of the University
4
5 Medical Center Groningen (METc UMCG: M20.252121). This study will provide new insights
6
7 in the effectiveness of online CBT for traumatically bereaved people. If the treatment is
8
9 demonstrated to be effective, it will be made publicly accessible. Findings will be
10
11 disseminated among lay people (e.g., through newsletters and media performances), our
12
13 collaborators (e.g., through presentations at support organizations), and clinicians and
14
15 researchers (e.g., through presentations at support organizations), and clinicians and
16
17 researchers (e.g., through conference presentations and scientific journal articles).
18
19
20

21 **Strengths and limitations of this study**

- 22
- 23
- 24 • This study is the first to examine the effectiveness of online CBT (vs. waitlist controls)
25
26 in reducing psychopathology after traumatic loss in an RCT.
- 27
- 28
- 29 • This study is one of the first to examine potential correlates of change in symptom
30
31 levels following online treatment after traumatic loss.
- 32
- 33
- 34 • We are not able to formally test mediators or moderators of treatment effects.
- 35
- 36 • We are not able to examine if online CBT has equal effects as face-to-face CBT.
- 37
- 38
- 39 • We are not able to establish formal diagnoses, as we use self-report questionnaires,
40
41 instead of diagnostic interviews, to assess symptom levels.
42
43
44

45 **Trial registration number:** NL7497 (Dutch Trial Register)

46
47 **Word Count:** 5,133 words including main text
48
49
50
51
52
53
54
55
56
57
58
59
60

Worldwide, traffic accidents represent the leading cause of unnatural deaths(1). Ten to 20 percent of bereaved people who experience natural deaths (e.g., illness) develop severe and persistent grief-related distress, including persistent complex bereavement disorder (PCBD), posttraumatic stress disorder (PTSD), and depression(2,3). Notably, PCBD has been introduced as other specified trauma- and stressor-related disorder, in the latest version of the Diagnostic and Statistical manual of Mental Diseases (DSM-5)(4). PCBD can be diagnosed if, after the death of a significant other at least 12 months earlier, a person experiences persistent yearning for the deceased and symptoms of reactive distress (e.g., emotional numbness) and social/identity disruption (e.g., feeling alone) causing impairment in daily life. While some PCBD symptoms overlap with PTSD (e.g., anger) and depression symptoms (e.g., diminished interest in activities), several studies have shown that these three syndromes are distinct(5–7). Unexpected/violent losses of a significant other, also referred to as a traumatic losses, including deaths caused by traffic accidents, increase risks for the development of PCBD, PTSD, and depression(8,9).

Heightened risk for developing psychopathology after deaths due to traffic accident

Specific circumstances of losses caused by accidents may account for the elevated risk of grief-related distress. For instance, experiencing multiple losses simultaneously, being a witness to the accident, and juridical and financial consequences are proposed to exacerbate grief-related distress(10). Furthermore, negative cognitions and avoidance behaviors may mediate the influence of sudden/violent loss on grief, PTSD, and depression levels(11). According to a cognitive-behavioral model three interacting malleable processes underlie disturbed grief reactions: i) negative cognitions, ii) avoidance behavior, and iii) difficulties integrating the loss into the autobiographical knowledge base(12).

1
2
3 Experiencing a loss due to a traffic accident may violate basic assumptions about the
4 world being a safe place(13). This may fuel negative cognitions (e.g., “I’m less worthy, since
5 s/he died” and “The death of him/her has taught me that the world is unjust) that may
6 exacerbate and maintain acute grief responses(14). Avoidance behaviors include depressive
7 avoidance and anxious avoidance strategies. Depressive avoidance refers to withdrawal from
8 social and occupational activities that were perceived as fulfilling before the death, out of
9 the conviction that these activities are no longer meaningful. Anxious avoidance strategies
10 serve to prevent confrontation with the reality of the death, out of fear that confrontation is
11 too painful(12). One potential way to avoid confrontation with the reality of the loss, is to
12 focus on angry thoughts and feelings (e.g., “I was angry at the police, courts, or
13 administration, because they did not do their work well enough”)(15). This seems to be a
14 frequently used avoidant coping strategy in bereaved people after traffic accidents and is
15 strongly related to PTSD(16). Difficulty with integration of the loss into the autobiographical
16 knowledge base refers to the difficulties connecting factual knowledge that the loss is
17 irreversible with existing information about the self and the relationship with the lost
18 person, stored in autobiographical memory. Memories related to the loss may lack context
19 in terms of time and place, causing the loss to be experienced as unreal(17). It has been
20 argued that this “sense of unrealness” may trigger intrusive memories and increase feelings
21 of numbness or shock once the bereaved person is confronted with reminders of the
22 loss(17,18). The extent to which a person believes that one is capable of managing stressor-
23 related thoughts, emotions, and behaviors, also referred to as self-efficacy (e.g., “I can
24 usually handle whatever comes my way”), has also been determined as an important factor
25 facilitating coping with traumatic stressors(19). Decreased self-efficacy, negative cognitions
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and insufficient integration of the loss may contribute to increased sensitivity to loss
4
5 reminders or secondary stressors following traumatic loss(20).
6
7

8 9 *Cognitive-behavioral therapy for grief-related distress*

10
11
12 Grief-specific CBT has been demonstrated to be the most effective treatment for bereaved
13
14 people with elevated grief levels(21–24). CBT targets the abovementioned cognitive-
15
16 behavioral variables with cognitive restructuring, loss-related exposure, and behavioral
17
18 activation. Notably, research on putative mechanisms of change of grief-specific CBT is
19
20 sparse(23) (but see(25,26)). Examining the effectiveness of grief-specific CBT and its
21
22 potential mechanisms of change in traumatically bereaved people with traumatic grief is
23
24 clinically relevant because it would enable tailoring of interventions to the specific needs of
25
26 this group, which could improve treatment outcomes(27).
27
28
29
30
31

32
33 Whilst the majority of trials assess the efficacy of face-to-face CBT(24), so far, to the
34
35 best of our knowledge, three online CBT-based interventions have been developed for
36
37 distressed bereaved people(28–30). These prior studies provided preliminary data on the
38
39 potential effectiveness of online grief-specific CBT, but had some limitations. For instance,
40
41 treatment was solely provided to people who experienced perinatal loss (29) or included
42
43 relatively small samples (28). Comparability between these three studies is also limited,
44
45 because interventions differed in treatment content; different elements of CBT were
46
47 offered, for instance behavioral activation, exposure (28), or writing assignments (29,30).
48
49 Offering CBT via the internet has some potential advantages. It may lower the threshold for
50
51 seeking treatment, because it can be delivered independent of geographical location.
52
53 Furthermore, asynchronous communication may be used, allowing the client and therapist
54
55 can contact each other at any preferred time(31). This may counter barriers to mental health
56
57
58
59
60

1
2
3 service use, such as difficulties with finding help, transportation concerns, or difficulties
4
5 scheduling treatment sessions(32). In addition, online CBT could reduce treatment costs,
6
7 improving accessibility and dissemination of care for people in need of support(33).
8
9
10 Moreover, during times of a crisis, such as the COVID-19 pandemic, it seems more relevant
11
12 than ever to further examine the effectiveness of online CBT for distressed bereaved people,
13
14 as it will allow them to retain access to evidence-based care (34).
15
16

17
18 A potential downside to online CBT is the high dropout rate found in earlier
19
20 studies(33,35). It has been argued that a strong therapeutic alliance might support
21
22 adherence to online treatment and mediates treatment effects (36). Therapeutic alliance is
23
24 defined as a positive emotional bond between client and therapist, whereby both parties
25
26 agree on the tasks and goals of the treatment(37). The client-therapist relationship might
27
28 also explain why online treatments are more effective with therapist guidance than without
29
30 (31). Concerns have been raised that developing a therapeutic relationship might be more
31
32 difficult when non-verbal communication is absent(38). However, studies in non-bereaved
33
34 samples indicate that developing a strong therapeutic alliance is possible during online
35
36 treatment(33) and that therapeutic alliance is often related to online treatment
37
38 outcomes(39), but not always (33). More research is needed to further examine the
39
40 interrelations of the quality of client-therapist relationship, drop-out, and treatment
41
42 outcomes in online CBT.
43
44
45
46
47
48
49

50 51 *Study objectives*

52
53
54 Our first aim is to examine the effectiveness of online CBT (vs. a waiting list control
55
56 condition) in reducing symptom levels of PCBD, PTSD, and depression in people bereaved by
57
58 a traffic accident. We expect that participants assigned to the online CBT condition will show
59
60

1
2
3 larger reductions in symptom levels of PCBD, PTSD, and depression compared with waitlist
4
5 controls at post-treatment assessments (Hypothesis 1).
6
7

8
9 Our second aim is to explore correlates of change. Based on prior research and
10 theories(12,16,19), we expect that reductions in negative cognitions, avoidance behaviors,
11 state anger, a sense of unrealness, and improvement in self-efficacy are related to
12 reductions in PCBD, PTSD, and depression levels in online CBT (Hypothesis 2a). Additionally,
13 we aim to explore whether background characteristics (i.e., gender, age, and educational
14 level, kinship to the deceased, and time since loss) and accident-related stressors (i.e., single
15 vs. multiple loss, witnessing the accident, and status of legal trial) are related to treatment
16 effects (Hypothesis 2b). We have no specific expectations regarding these associations
17 because prior treatment studies in bereaved people showed inconsistent results(24,25,40).
18 However, based on clinical experience, we expect that accident-related stressors are
19 associated with treatment effects, such that multiple loss, witnessing the accident, and on-
20 going legal trial negatively impact treatment effects.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Our third aim is to explore the associations between quality of the therapeutic
40 alliance and drop-out rates and treatment outcomes. We expect that a stronger therapeutic
41 alliance is related to lower dropout rates and better treatment outcomes.
42
43
44
45
46

47 **Methods and analysis**

48 **Design**

49
50
51 A two-arm (online CBT vs. waiting list) multi-centre open label parallel RCT will be
52 conducted. Randomization will take place after the participant is screened for eligibility-
53 based inclusion criteria (described below). A random number generator (www.random.org)
54
55
56
57
58
59
60

1
2
3 will be used by a blinded independent researcher, to perform the blocking randomization
4
5 procedure. An allocation ratio of 1:1 will be applied.
6
7

8
9 Participants allocated to the online CBT condition receive treatment within one week
10
11 after allocation. All participants will be asked to fill in questionnaires (described below) at
12
13 baseline (T1), 12 weeks post-allocation (T2 for the intervention condition and T1a for waitlist
14
15 controls), and 20 weeks post-allocation (T3 for the intervention condition and T1b for
16
17 waitlist controls). For participants in the waiting list control group, at the end of the 20-week
18
19 waiting period after which they will receive online CBT, they will be asked to fill in T2 and T3
20
21 12 and 20 weeks after starting treatment, respectively (see Figure 1). A link to online
22
23 questionnaires will be sent to the participants by a non-blinded member of the research
24
25 team at each time-point. A waitlist control group (instead of a no treatment control group) is
26
27 chosen to increase the likelihood of continued study participation by guaranteeing that all
28
29 participants receive treatment. Furthermore, the inclusion of a waiting list control group
30
31 allows a treatment versus no treatment comparison, that will provide knowledge about the
32
33 effects of treatment relative to natural recovery from loss.
34
35
36
37
38
39
40

41 In line with prior treatment studies from our research group(40,41), the online
42
43 treatment is guided by governmentally licensed psychologists, connected with a Dutch
44
45 informal “traumatic loss network” of therapists specialized in treating emotional distress
46
47 following traumatic loss. In total six therapists (including authors PB and JdK who are
48
49 registered clinical psychologists) will guide the participants online; participants will receive
50
51 feedback from the same therapist each time. The therapists will receive a training, provided
52
53 by LL, PB, and JdK, on the use of the treatment protocol of this intervention study. In
54
55 preparation for the training, therapists read all treatment materials and a selection of grief
56
57
58
59
60

1
2
3 treatment literature. Instructions about the use of the online treatment interface will be
4
5 given by its developers. During a 5-hour face-to-face group meeting the rationale of the
6
7 online treatment will be explained and research procedures will be discussed. In a 2-hour
8
9 online video-meeting outstanding questions regarding the treatment and the research
10
11 project will be answered. Supervision (by telephone or mail) by PB and JdK is possible on
12
13 request, for instance when therapists encounter difficulties in treatment. Therapists will be
14
15 contacted by a member of the research team by phone or email biweekly to monitor
16
17 treatment progress and protocol adherence. Treatment costs will be reimbursed.
18
19
20
21
22

23 ==Figure 1 about here==
24
25

26 **Participants**

27
28
29
30 This RCT is part of a larger on-going research project (the "TrafVic-project") examining the
31
32 psychological impact of, and care after, the death of a loved one due to a traffic accident.
33
34 We expect to recruit the majority of the participants via a survey that started in December
35
36 2018 and included the following question: "In this study we would like to offer psychological
37
38 help to persons who experience emotional problems. May we approach you with more
39
40 information about this offer, if your answers to this questionnaire show that you experience
41
42 emotional problems?" Those who answered 'yes' will be sent a letter with information about
43
44 the intervention, the treatment study, and an informed consent form (see Supplementary
45
46 Materials). A Dutch website (www.rounnaverkeersongeval.nl) has been developed so that
47
48 potential participants can read information about the research and treatment. People who
49
50 are interested can also sign up for the study via this website. Recruitment for this RCT had
51
52 not started at the time of submission of this manuscript.
53
54
55
56
57
58
59
60

1
2
3 To be eligible for study participation, the person must 1) be a family member,
4 spouse, or friend of a person who died due to a traffic accident at least one year earlier, 2)
5 be ≥ 18 years of age, and 3) meet DSM-5 criteria for PCBD and/or PTSD and/or experience
6 clinically relevant depression, based on questionnaire scores (see below for more details).
7
8 People are excluded when they do not master the Dutch language or have no Internet
9 access.
10
11
12
13
14
15
16
17

18 **Sample size**

19
20
21 To test our primary hypothesis (Hypothesis 1), a test for each outcome separately (PCBD,
22 PTSD, and depression) will be conducted to assess the effects of online CBT vs. waitlist
23 controls. To find a difference between two groups (online CBT vs. waitlist controls) of at least
24 a medium effect size ($f = 0.25$; based on prior research(22,28,40)) with a power of 80%, an α
25 of 0.017 (corrected for multiple testing, i.e., $0.05/3$, as there are three primary outcome
26 measures (PCBD, PTSD, and depression)), and a strong association ($r = .50$) between the pre-
27 and post-assessment, a sample size of 23 per condition is sufficient. Taking into account an
28 average dropout rate of 19% (22), a total sample size of 55 (46+9) is required to test
29 Hypothesis 1.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Because our data are nested (repeated measures) (level 1) within individuals (level
46 2), and possibly within families sharing the same household (level 3), multi-level modeling
47 will be performed to test hypothesis 1. Conducting a power analysis within a multi-level
48 framework is not feasible for various reasons(42). Our power analysis is therefore based on a
49 repeated measures ANOVA.
50
51
52
53
54
55
56

57 **Intervention**

1
2
3 Online CBT will consist of eight one-on-one sessions, called lessons, offered within a
4
5 timeframe of 12 weeks. Eight sessions have shown to be sufficient to yield clinically relevant
6
7 effects in prior research(40). Following Dutch guidelines for grief-specific CBT(42), central
8
9 components of the treatment are exposure, cognitive restructuring, and behavioral
10
11 activation. In the first session, psychoeducation is offered, including information about
12
13 possible emotional reactions to the death of a loved one in a traffic accident and processes
14
15 that might foster or hamper recovery. A rationale for the CBT interventions is provided.
16
17
18
19
20

21 Then, session 2, 3, and 4 are focused on exposure; the circumstances and story of the
22
23 loss are presented in detail, and the participant is encouraged to confront stimuli that s/he
24
25 tends to avoid. Exposure is conducted by imaginary exposure assignments and by writing
26
27 assignment that have proven to be effective in prior research(30). These writing assignments
28
29 are focused on writing a detailed narrative of the loss and its circumstances.
30
31
32
33

34 The next sessions (5 and 6) focus on identifying and changing negative cognitions
35
36 that hamper adjustment (i.e., cognitive restructuring); specific attention is paid to cognitions
37
38 connected with responsibility/guilt and anger that may be experienced following the
39
40 accidental death(10). Cognitive restructuring assignments are provided to gain an alternative
41
42 perspective on negative thoughts about the self, life, the future, through 1) psycho-
43
44 education about common unhelpful thoughts, 2) identifying one's own unhelpful thoughts,
45
46 and 3) challenging these thoughts. Participants are instructed to undertake these three steps
47
48 by providing a daily description of i) an emotional moment/event, ii) their thoughts during
49
50 this event, iii) their feelings (and intensity of these feelings on a scale of 1 through 10), iv)
51
52 their behavior, v) evaluation of their thoughts), and vi) alternative helpful thoughts.
53
54
55
56
57
58
59
60

1
2
3 In session 7 and 8, participants are encouraged to re-engage in previously valued
4 social, recreational, and occupational activities in order to facilitate the process of
5 adjustment. Behavioral activation assignments are focused on writing about valued activities
6 and making plans to achieve valued goals. Session 8 is also focused on what the participant
7 has learned and how to deal with difficulties in the future.
8
9
10
11
12
13
14
15

16 All information and assignments are presented in an online framework, offered via a
17 secure website. Participants receive online written information that consists of
18 psychoeducation, information about treatment content and structure, and homework
19 assignments. As part of the online treatment, participants also listen to a video-therapist
20 verbally sharing parts of information that are also presented in text. The video-therapists are
21 two members from the traumatic loss network; one male and one female psychotherapist
22 who are middle-aged and specialized in treating bereaved people. At the start of the
23 treatment the video-therapists introduce themselves and the participant is asked to select
24 one of the video-therapists. The information shared by these video-therapists are recorded
25 in video-messages in which they read parts of the texts out loud. Each participant therefore
26 receives the same information from a video-therapist. Direct contact with the video-
27 therapist is not possible.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Participants receive weekly asynchronous written feedback from one online therapist
47 on each assignment that they complete online. As mentioned earlier, six online therapists
48 are trained to guide the participants. The online therapists are instructed to contact the
49 participant twice a week; once to encourage participants to log in and complete assignments
50 and once to provide feedback on assignments. In total, they spend 30 minutes per week on
51 reading assignments and providing feedback. Moreover, participants are encouraged to ask
52
53
54
55
56
57
58
59
60

1
2
3 a family member or friend to support them during treatment. This support figure is then
4
5 informed about the treatment through written information in an online framework.
6
7

8 9 **Measures**

10 11 *Primary outcome measures*

12
13
14
15 PCBD will be assessed with the Traumatic Grief Inventory-Self Report (TGI-SR)(43). The TGI-
16
17 SR consists of 18 items on a 5-point Likert scale ranging from 1 = never through 5 = always.
18
19 Four items tapping disturbed grief criteria according to the 11th edition of the International
20
21 Classification of Diseases were added(44). An example of an item is: "I found it difficult to
22
23 trust others". The instruction of the original questionnaire was altered from referring to "the
24
25 death of your loved one" to "the death of your loved one(s) due to a traffic accident".
26
27
28
29 Psychometric properties of the TGI-SR are adequate(43,45). Participants are considered to
30
31 meet criteria for DSM-5 PCBD(4) when they score at least 3 ("Sometimes") on at least 1
32
33 criterion B symptom (Item 1, item 2, item 3, and item 14), at least 6 criterion C symptoms
34
35 (item 4 up to 11, and item 15 up to 18), and the criterion D symptom (item 13).
36
37
38
39

40
41 PTSD will be assessed with the PTSD Checklist for DSM-5 (PCL-5)(46) (Dutch version:
42
43 (47)). Participants rate how often they were bothered by each symptom (e.g., "In the past
44
45 month, how much were you bothered by trouble remembering important parts of the
46
47 accident?") on 5-point Likert scales (0 = not at all and 4 = extremely). The instruction and the
48
49 items of the original questionnaire are altered from referring to the "stressful event" to the
50
51 "the death of your loved one(s) due to a traffic accident". The PCL-5 has shown to be reliable
52
53 and valid(46). Participants meet the criteria for DSM-5 PTSD(4) when they score at least 2
54
55 ("Moderately") on 1 criterion B item (items 1-5), 1 criterion C item (items 6-7), 2 criterion D
56
57 items (items 8-14), and 2 criterion E items (items 15-20).
58
59
60

1
2
3 Depression symptom levels are assessed with the depression subscale of the HADS-
4 D(48). The HADS-D consists of 7 items (e.g., “I still enjoy the thing I used to do”) rated on 4-
5 point scores ranging from 0 (e.g., “Hardly at all”) through 3 (e.g., “Definitely as much”). The
6 Dutch HADS-D is a reliable and valid screening tool for depression(49). A cut-off score of ≥ 8
7 is used as indicator for clinically relevant depression(48).
8
9

16 *Secondary outcome measures*

17
18
19 Negative grief-related cognitions are assessed with 18 items from the Grief
20 Cognitions Questionnaire (GCQ)(14). Participants are asked to rate their agreement with
21 each item (e.g., “Since [-] is dead, I feel less worthy”) on 6-point scales varying from 0 =
22 disagree strongly through 5 = agree strongly. The psychometric properties have been
23 positively evaluated in prior research(14).
24
25
26
27
28
29
30

31
32 Avoidance is measured with the Depressive and Anxious Avoidance in Prolonged
33 Grief Questionnaire (DAAPGQ)(50). The depressive avoidance subscale consists of 5 items
34 (e.g. ‘Since [-] is dead, I do much less of the things that I used to enjoy.’) and the anxious
35 avoidance subscale consists of 4 items (e.g., ‘I avoid to dwell on painful thoughts and
36 memories connected to his/her death.’). Participants answer each item on an 8-point scale
37 with 0 = not at all true for me, and 7 = completely true for me. The DAAPGQ has adequate
38 psychometric properties(50).
39
40
41
42
43
44
45
46
47
48
49

50 State anger is assessed with the 15-item state anger subscale of the State-Trait Anger
51 Expression Inventory-2 (STAXI-2)(51) (Dutch version:(52)). Participants are asked to rate on
52 4-point Likert scales (1 = not at all and 4 = extremely) how angry they feel right now (e.g., “I
53 feel annoyed”). The STAXI-2 is a valid and reliable measure to assess state anger(52).
54
55
56
57
58
59
60

1
2
3 A sense of unrealness is measured with the 5-item Experienced Unrealness Scale(17).
4
5 Participants are asked to rate their agreement with each item (e.g., “I still can hardly imagine
6
7 that [-] will never be here again”) on 8-point scales (0 = not at all true for me 7 = completely
8
9 true for me). This instrument demonstrated adequate psychometric properties(17).
10
11
12

13
14 Self-efficacy is assessed with the General Self-Efficacy Scale (GSES)(53). The GSES is a
15
16 10-item measure. Participants are asked to rate their agreement with each item (e.g., “I can
17
18 solve most problems if I invest the necessary effort.”) on a 4-point scale (1 = completely not
19
20 true, 4 = completely true). The GSES has shown excellent reliability and validity(53).
21
22
23

24
25 Quality of the therapeutic alliance is measured with the 12-item Work Alliance
26
27 Inventory-Short Form, Client Version and Therapist Version after session 4 (WAI-SF)(54)
28
29 (Dutch version:(55). The WAI-SF consists of 12 items (e.g., Client version: “We agree on what
30
31 is important for me to work on”, Therapist Version: “We are working towards mutually
32
33 agreed upon goals.”) that are rated on 5-point scales (1 = never and 5 = always). Higher total
34
35 scores indicate a higher quality of the therapeutic alliance as perceived by the participant
36
37 and therapist. The WAI-SF is a reliable and valid assessment tool(56).
38
39
40
41

42 *Other measures*

43
44

45
46 Background characteristics (i.e., gender, age, and educational level, kinship to the deceased,
47
48 and time since loss) and accident-related stressors (i.e., single vs. multiple loss, witnessed
49
50 the accident, and status of legal trial) will be assessed with single items.
51
52
53

54
55 Participants are allowed to receive other forms of psychosocial, instrumental or legal
56
57 support during participation in the trial. Using a single question we will assess whether the
58
59 participants received other forms of psychosocial professional support. The following
60

1
2
3 question will be used: “During the past 12 weeks/8 weeks (for T2 and T3, respectively) did
4 you receive additional psychological professional support from a psychologist, therapist or
5 psychiatrist other than the (online) therapist from the TrafVic-study?” We will also include
6 two dichotomous items (yes/no) at T1 to assess psychological support received prior to
7 participation in the study, namely: “Did you ever receive support from a psychologist,
8 therapist or psychiatrist, for your own emotional/mental problems, prior to the loss of your
9 loved one due to a traffic accident?” and “Did you ever receive support from a psychologist,
10 therapist or psychiatrist, for your own emotional/mental problems, related to the loss of
11 your loved one due to a traffic accident?”
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 **Statistical analyses**

30
31
32 To examine the differences in reductions of symptom levels of PCBD, PTSD, and depression
33 from pre- to post-treatment/waiting period between the conditions (online CBT vs. waitlist),
34 three independent multi-level models will be built (Hypothesis 1). Symptom levels of PCBD,
35 PTSD, and depression will consecutively be included as dependent variables and condition
36 (online CBT vs. waitlist controls), time, and time x condition (interaction term) as predictor
37 variables, taking into account that repeated observations (level 1) are nested within
38 individuals (level 2), and within households (level 3; if applicable). Additionally, relevant
39 background, loss-related variables, and use of co-interventions (yes/no) during participation
40 in our study, will be included in the analysis as covariates. Deviance tests will be used to
41 examine whether inclusion of these covariates improves model fit(57). Data of all
42 participants entering the study will be included in all analyses (i.e., intention-to-treat
43 analysis). Furthermore, percentages of people meeting diagnostic criteria for PCBD, PTSD,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and clinically relevant depression will be calculated for each measurement occasion and
4
5 percentages of people reporting reliable change scores for each outcome measure, using a
6
7 formula from Jacobson and Truax(58, p. 14), will be reported.
8
9

10
11 To examine to what extent symptom improvement after treatment is related to
12
13 improvement in possible correlates of change, residual gain scores will be calculated for all
14
15 outcome measures (i.e., PCBD, PTSD, and depression) and possible correlates of change (i.e.,
16
17 negative cognitions, avoidance behaviors, state anger, a sense of unrealness, and self-
18
19 efficacy). Following previous research (cf. (59)), residual gain scores will be calculated by
20
21 subtracting the standardized combined pre-treatment scores of both conditions (T1 data
22
23 from immediate treatment condition and T1b data from waitlist condition) multiplied by the
24
25 correlation coefficient between standardized combined pre-treatment scores and
26
27 standardized post-treatment (or follow-up) scores from standardized post-treatment (or
28
29 follow up) scores. To test hypothesis 2a, multiple regression analyses will be conducted to
30
31 examine the associations between residual gain scores of PCBD, PTSD, or depression and
32
33 residual gain scores of negative cognitions, avoidance behaviors, state anger, a sense of
34
35 unrealness, and self-efficacy.
36
37
38
39
40
41
42
43

44 To achieve research aim 2b, multiple regression analyses will be used to examine to
45
46 what extent residual gain scores of PCBD, PTSD, and depression varies as function of a)
47
48 background characteristics, including gender (male/female), age (in years), and educational
49
50 level (low/high), kinship to the deceased (child/spouse vs other), and time since loss (in
51
52 years) and b) accident-related stressors, including number of losses (single vs multiple),
53
54 witnessing the accident (yes/no), and status of legal trial (not applicable/on-
55
56
57
58
59
60

1
2
3 going/completed). Condition (intervention vs. waitlist controls) will be added as a covariate
4
5 to fulfill research aim 2a and 2b.
6
7

8
9 To achieve the third research aim, a) differences in therapeutic alliance scores will be
10
11 assessed between people who completed and dropped out of treatment and b) multiple
12
13 regression analyses will be used to examine to what extent symptom improvement in PCBD,
14
15 PTSD, and depression is related to therapeutic alliance (from both participant and therapist
16
17 perspectives).
18
19

20 21 22 **Ethics and dissemination** 23

24
25 The initial plan for this study was to conduct a three-arm (face-to-face CBT, online CBT, and
26
27 waiting list) RCT to examine the effectiveness of face-to-face CBT (vs. waitlist controls) *and*
28
29 online CBT (vs. waitlist controls). This study has been approved by the Medical Ethics Review
30
31 Board of the University Medical Center Groningen (METc UMCG: ID number: M20.252121).
32
33 Due to the COVID-19 outbreak we had to change our study protocol, because face-to-face
34
35 contact with a therapist was not possible because of social distancing measures. Instead of
36
37 comparing the effects of online and face-to-face CBT with waitlist controls, we changed the
38
39 design of the study by comparing the effects of online CBT vs. waitlist controls before
40
41 enrolment of participants took place. This amendment to our study has been approved by
42
43 the same ethics committee.
44
45
46
47
48
49

50
51 The study will be conducted according to the principles of the Declaration of Helsinki
52
53 (8th version, 2013) and in accordance with the Medical Research Involving Human Subjects
54
55 Act. Collected data will be handled confidentially, according to the EU General Data
56
57 Protection Regulation and the Dutch Act on Implementation of the General Data Protection
58
59
60

1
2
3 Regulation. Unidentifiable data from this trial will be stored in data repositories from the
4
5 University of Groningen and Utrecht University.
6
7

8
9 Findings of this RCT will be disseminated among participants by means of a
10
11 newsletter. If shown to be effective, the online framework will be made publicly accessible,
12
13 so that it can benefit other bereaved people. Findings will also be disseminated among lay
14
15 people by uploading the newsletters on our website (www.rouwnaverkeersongeval.nl) and
16
17 through media performances. Our findings will be presented to our collaborators, including
18
19 non-governmental organizations and (peer-)support organizations for bereaved people.
20
21 Treatment materials will also be made available upon request. Lastly, colleagues will be
22
23 informed about our findings during presentations at (inter)national conferences and
24
25 publications in scientific journals.
26
27
28
29

30 31 **Patient and public involvement** 32

33
34 At the start of this project an advisory committee was established. This committee includes
35
36 someone who lost a significant other after a traffic accident, a lawyer with expertise in
37
38 supporting bereaved people after traffic accidents, and representatives of Victim Support
39
40 the Netherlands and Fund Victim Support. This committee was involved in the development
41
42 of the research questions, outcomes measures, and design of the study by reading and
43
44 commenting on drafts of our research proposal and study-protocol. This committee pilot
45
46 tested the questionnaires and was involved in the development of recruitment materials,
47
48 recruitment strategies, and information materials for participants by reading, revising, and
49
50 approving the drafts. This committee helps the research team in recruiting participants by
51
52 sharing information about this study in their own professional network. The advisory
53
54 committee is not involved in conducting the study or development of treatment materials.
55
56
57
58
59
60

1
2
3 The committee will support the research team when disseminating the study findings among
4 relevant audiences by help writing and reviewing newsletters and press releases.
5
6
7

8 **Discussion**

9
10
11
12 The relatively few RCTs among general bereaved people with elevated grief levels indicate
13 that grief-specific CBT-based interventions yield the largest effects on post-loss mental
14 health compared with a waiting list(21–24). RCTs evaluating face-to-face or online treatment
15 effects for people with elevated mental health complaints after confrontation with
16 sudden/violent losses are lacking, with the exception of two studies that compared face-to-
17 face EMDR plus CBT against waitlist controls(40,59). Given that traumatically bereaved
18 people are at risk for PCBD and comorbid PTSD and depression(8), it seems particularly
19 relevant to develop evidence-based interventions for this population.
20
21
22
23
24
25
26
27
28
29
30

31
32 This will be the first RCT to examine the effectiveness of online CBT in a sample
33 exclusively comprised of people who experienced a traumatic death. We are not able to test
34 whether the online CBT has equal effects as face-to-face CBT. Nonetheless, the findings are
35 expected to yield important insights in the effects of online CBT. In this RCT, the online
36 treatment is designed to be as similar as possible to face-face CBT in terms of treatment
37 content, treatment duration, and experience and training of therapists. When we find effect
38 sizes for online CBT that are similar to effect sizes found in earlier studies for face-to-face
39 CBT, delivering CBT online can be considered as supplement to face-to-face treatment, in
40 particular when barriers to face-to-face treatments, such as waiting lists and travel expenses,
41 are experienced.
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56
57 We will also examine potential correlates of change. These analyses, examining the
58 associations between reductions in symptoms levels and among others negative cognitions
59
60

1
2
3 and avoidance behaviors, will provide insights in potential underlying therapeutic processes
4
5 to foster recovery from traumatic loss. These insights are deemed important to design
6
7 treatments that more effectively target these correlates of change. We also expect to
8
9 improve our knowledge on for whom (e.g., women or people who are more remotely
10
11 bereaved) grief-specific CBT works best. Findings on these potential correlates of change are
12
13 necessary to improve treatments given that a maximum of 42% of bereaved people report
14
15 clinically relevant reductions in grief levels after treatment(21).
16
17
18
19
20

21 Lastly, the role of therapeutic alliance on therapy outcomes will be explored. Prior
22
23 research in bereaved people has shown that greater therapeutic alliance, from the
24
25 perspective of the client, at week 4 of a face-to-face grief-specific treatment, was related to
26
27 greater reductions in grief levels. This therapeutic alliance-grief relationship was not
28
29 significant for a non-grief specific treatment(60). Our exploration of this association, from
30
31 the perspective of client *and* therapist, may for the first time shed light on therapeutic
32
33 processes in online CBT for traumatic grief.
34
35
36
37
38

39 An anticipated limitation of our RCT is the self-selected sample. It is possible that
40
41 people who are more open towards innovative technology in general(61) and who received
42
43 support prior to the loss(32) are more likely to sign up for this study, limiting the
44
45 generalizability of findings emerging from this study. Due to the absence of an active control
46
47 group (e.g., face-to-face CBT) we are not able to test the effects of online CBT compared
48
49 with an alternative treatment. Furthermore, we will use self-report measures instead of
50
51 diagnostic interviews, which may increase the risk of overestimating symptom levels(62). In
52
53 addition, participants might experience difficulties with completing the mid-treatment
54
55 assessment of the therapeutic relationship because the video-therapist that provides
56
57
58
59
60

1
2
3 information through recorded video messages (interaction between video-therapist and
4
5 participant is not possible) might be a different person than the online therapist who
6
7 provides personal written feedback twice a week. Although the instructions of the
8
9 therapeutic alliance measure explicitly refer to the interaction with the online therapist (not
10
11 the video-therapist), this might still be confusing for some participants. Another potential
12
13 limitation of this trial relates to the fact that the operationalization and assessment of grief
14
15 as a disorder is still under debate(63–65). For instance, PCBD, included as “condition for
16
17 further study” in the DSM-5, is likely to be changed in a revision of the DSM. To maximize
18
19 diagnostic compatibility, we added four items, corresponding to ICD-11 PGD criteria, to the
20
21 TGI-SR, enabling operationalization of our primary outcome measure in terms of diagnoses of
22
23 pathological grief according to both the DSM-5 and the ICD-11.
24
25
26
27
28
29

30
31 To conclude, this RCT will provide new insights in effectiveness of online CBT for
32
33 people who experience clinically relevant distress after bereavement due to a traffic
34
35 accident, as well as in potential correlates of therapeutic change. As trials to date have
36
37 primarily focused on effects of face-to-face treatment for non-traumatically bereaved
38
39 people, our findings are expected to provide a valuable addition to the knowledge base on
40
41 treating severely distressed bereaved people.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization. The top 10 causes of death [Internet]. 2019 [geciteerd 14 oktober 2019]. Beschikbaar op: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
2. Lundorff M, Holmgren H, Zachariae R, Farver-Vestergaard I, O'Connor M. Prevalence of prolonged grief disorder in adult bereavement: A systematic review and meta-analysis. *J Affect Disord.* 2017;212:138–49.
3. Onrust SA, Cuijpers P. Mood and anxiety disorders in widowhood: a systematic review. *Aging Ment Health.* 2006;10(4):327–34.
4. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders (5th ed.)*. Arlington, VA: American Psychiatric Publishing; 2013.
5. Boelen PA, van de Schoot R, van den Hout MA, de Keijser J, van den Bout J. Prolonged Grief Disorder, depression, and posttraumatic stress disorder are distinguishable syndromes. *J Affect Disord.* 2010;125(1–3):374–8.
6. Lenferink LIM, Nickerson A, de Keijser J, Smid GE, Boelen PA. Trajectories of grief, depression, and posttraumatic stress in disaster-bereaved people. *Depress Anxiety.* 2018;
7. Malgaroli M, Maccallum F, Bonanno GA. Symptoms of persistent complex bereavement disorder, depression, and PTSD in a conjugally bereaved sample: a network analysis. *Psychol Med.* 2018;48(14):2439–48.

- 1
2
3 8. Heeke C, Kampisiou C, Niemeyer H, Knaevelsrud C. A systematic review and meta-
4
5 analysis of correlates of prolonged grief disorder in adults exposed to violent loss. *Eur J*
6
7 *Psychotraumatology* [Internet]. 2019 [geciteerd 14 oktober 2019];10(1). Beschikbaar
8
9 op: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442112/>
10
11
12
- 13
14 9. Kristensen P, Weisæth L, Heir T. Bereavement and mental health after sudden and
15
16 violent losses: a review. *Psychiatry*. 2012;75(1):76–97.
17
18
- 19
20 10. Eisma, M.C., de Keijser, J. Nabestaanden van verkeersongevallen. In: de Keijser, J.,
21
22 Boelen, P.A., Smid, G.E., redacteuren. *Handboek traumatische rouw*. Amsterdam:
23
24 Uitgeverij Boom; 2018. p. 104–16.
25
26
- 27
28 11. Boelen PA, de Keijser J, Smid G. Cognitive–behavioral variables mediate the impact of
29
30 violent loss on post-loss psychopathology. *Psychol Trauma Theory Res Pract Policy*.
31
32 2015;7(4):382–90.
33
34
- 35
36 12. Boelen PA, van den Hout MA, van den Bout J. A Cognitive-Behavioral Conceptualization
37
38 of Complicated Grief. *Clin Psychol Sci Pract*. 2006;13(2):109–28.
39
40
- 41
42 13. Janoff-Bulman R. Assumptive worlds and the stress of traumatic events: Applications of
43
44 the schema construct. *Soc Cogn*. 1989;7(2):113–36.
45
46
- 47
48 14. Boelen PA, Lensvelt-Mulders GJLM. Psychometric Properties of the Grief Cognitions
49
50 Questionnaire (GCQ). *J Psychopathol Behav Assess*. 2005;27(4):291–303.
51
52
- 53
54 15. Foa EB, Riggs DS, Massie ED, Yarczower M. The impact of fear activation and anger on
55
56 the efficacy of exposure treatment for posttraumatic stress disorder. *Behav Ther*.
57
58 1995;26(3):487–99.
59
60

- 1
2
3 16. Tehrani, N. Road victim trauma: an investigation of the impact on the injured and
4
5 bereaved. *Couns Psychol Q.* 2004;17(4):361–73.
6
7
- 8
9 17. Boelen PA. A Sense of ‘unrealness’ about the death of a loved-one: An exploratory
10
11 study of its role in emotional complications among bereaved individuals. *Appl Cogn*
12
13 *Psychol.* 2010;24(2):238–51.
14
15
- 16
17 18. Boelen PA. “It feels as if she might return one day”: A sense of unrealness as a predictor
18
19 of bereavement-related emotional distress / “Tengo la sensación de que ella puede
20
21 volver algún día”: la sensación de irrealidad como un predictor del sufrimiento
22
23 emocional relacionado con la pérdida. *Estud Psicol.* 2017;38(3):734–51.
24
25
- 26
27 19. Benight CC. Social cognitive theory of posttraumatic recovery: the role of perceived
28
29 self-efficacy. *Behav Res Ther.* 2004;42(10):1129–48.
30
31
- 32
33 20. Smid GE, Kleber RJ, Rie SM de la, Bos JBA, Gersons BPR, Boelen PA. Brief Eclectic
34
35 Psychotherapy for Traumatic Grief (BEP-TG): toward integrated treatment of symptoms
36
37 related to traumatic loss. *Eur J Psychotraumatology.* 2015;6(1):27324.
38
39
- 40
41 21. Boelen PA, Smid GE. Disturbed grief: prolonged grief disorder and persistent complex
42
43 bereavement disorder. *BMJ.* 2017;357:j2016.
44
45
- 46
47 22. Currier JM, Holland JM, Neimeyer RA. Do CBT-Based Interventions Alleviate Distress
48
49 Following Bereavement? A Review of the Current Evidence. *International Journal of*
50
51 *Cognitive Therapy.* 2010;3:77–93.
52
53
- 54
55 23. Doering BK, Eisma MC. Treatment for complicated grief: state of the science and ways
56
57 forward. *Curr Opin Psychiatry.* 2016;29(5):286–91.
58
59
60

- 1
2
3 24. Johannsen M, Damholdt MF, Zachariae R, Lundorff M, Farver-Vestergaard I, O'Connor
4
5 M. Psychological interventions for grief in adults: A systematic review and meta-
6
7 analysis of randomized controlled trials. *J Affect Disord.* 2019;253:69–86.
8
9
- 10
11 25. Boelen PA, Keijser J de, Hout MA van den, Bout J van den. Factors associated with
12
13 outcome of cognitive-behavioural therapy for complicated grief: A preliminary study.
14
15 *Clin Psychol Psychother.* 2011;18(4):284–91.
16
17
- 18
19 26. Bryant RA, Kenny L, Joscelyne A, Rawson N, Maccallum F, Cahill C, e.a. Predictors of
20
21 treatment response for cognitive behaviour therapy for prolonged grief disorder. *Eur J*
22
23 *Psychotraumatology* [Internet]. 2019 [geciteerd 13 oktober 2019];8(6). Beschikbaar op:
24
25 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383610/>
26
27
- 28
29 27. Linde K, Treml J, Steinig J, Nagl M, Kersting A. Grief interventions for people bereaved
30
31 by suicide: A systematic review. *PloS One.* 2017;12(6):e0179496.
32
33
- 34
35 28. Eisma MC, Boelen PA, van den Bout J, Stroebe W, Schut HAW, Lancee J, e.a. Internet-
36
37 Based Exposure and Behavioral Activation for Complicated Grief and Rumination: A
38
39 Randomized Controlled Trial. *Behav Ther.* 2015;46(6):729–48.
40
41
- 42
43 29. Kersting A, Dölemeyer R, Steinig J, Walter F, Kroker K, Baust K, e.a. Brief Internet-based
44
45 intervention reduces posttraumatic stress and prolonged grief in parents after the loss
46
47 of a child during pregnancy: a randomized controlled trial. *Psychother Psychosom.*
48
49 2013;82(6):372–81.
50
51
- 52
53 30. Wagner B, Knaevelsrud C, Maercker A. Internet-based cognitive-behavioral therapy for
54
55 complicated grief: a randomized controlled trial. *Death Stud.* 2006;30(5):429–53.
56
57
58
59
60

- 1
2
3 31. Baumeister H, Reichler L, Munzinger M, Lin J. The impact of guidance on Internet-based
4
5 mental health interventions — A systematic review. *Internet Interv.* 2014;1(4):205–15.
6
7
- 8
9 32. Lichtenthal WG, Corner GW, Sweeney CR, Wiener L, Roberts KE, Baser RE, e.a. Mental
10
11 Health Services for Parents Who Lost a Child to Cancer: If We Build Them, Will They
12
13 Come? *J Clin Oncol Off J Am Soc Clin Oncol.* 2015;33(20):2246–53.
14
15
- 16
17 33. Andersson G, Titov N. Advantages and limitations of Internet-based interventions for
18
19 common mental disorders. *World Psychiatry.* 2014;13(1):4–11.
20
21
- 22
23 34. Eisma MC, Boelen PA, Lenferink LIM. Prolonged grief disorder following the Coronavirus
24
25 (COVID-19) pandemic. *Psychiatry Res.* 2020;288:113031.
26
27
- 28
29 35. Melville KM, Casey LM, Kavanagh DJ. Dropout from Internet-based treatment for
30
31 psychological disorders. *Br J Clin Psychol.* 2010;49(Pt 4):455–71.
32
33
- 34
35 36. Pihlaja S, Stenberg J-H, Joutsenniemi K, Mehik H, Ritola V, Joffe G. Therapeutic alliance
36
37 in guided internet therapy programs for depression and anxiety disorders - A
38
39 systematic review. *Internet Interv.* 2018;11:1–10.
40
41
- 42
43 37. Bordin ES. Theory and research on the therapeutic working alliance: New directions. In:
44
45 *The working alliance: Theory, research, and practice.* Oxford, England: John Wiley &
46
47 Sons; 1994. p. 13–37. (Wiley series on personality processes).
48
49
- 50
51 38. Cook JE, Doyle C. Working alliance in online therapy as compared to face-to-face
52
53 therapy: preliminary results. *Cyberpsychology Behav Impact Internet Multimed Virtual*
54
55 *Real Behav Soc.* 2002;5(2):95–105.
56
57
58
59
60

- 1
2
3 39. Sucala M, Schnur JB, Constantino MJ, Miller SJ, Brackman EH, Montgomery GH. The
4
5 therapeutic relationship in e-therapy for mental health: A systematic review. *J Med*
6
7
8 Internet Res. 2012;14(4):e110.
9
10
11 40. van Denderen M, de Keijser J, Stewart R, Boelen PA. Treating complicated grief and
12
13 posttraumatic stress in homicidally bereaved individuals: A randomized controlled trial.
14
15
16 Clin Psychol Psychother. 2018;
17
18
19 41. Lenferink LIM, de Keijser J, Wessel I, Boelen PA. Cognitive behavioural therapy and
20
21 mindfulness for relatives of missing persons: A pilot study. *Pilot Feasibility Stud.*
22
23
24 2019;5(1):93.
25
26
27 42. Boelen PA, Bout J van den. Protocollaire behandeling van persisterende complexe
28
29 rouwstoornis. In: Keijsers, G., Minnen, A. van, Verbraak, M., Hoogduin, K., Emmelkamp,
30
31 P., redacteuren. Protocollaire behandelingen voor volwassenen met psychische
32
33 klachten. 1ste dr. Amsterdam: Boom; 2017.
34
35
36
37
38 43. Boelen PA, Smid GE. The Traumatic Grief Inventory Self-Report Version (TGI-SR):
39
40 Introduction and Preliminary Psychometric Evaluation. *J Loss Trauma.* 2017;22(3):196–
41
42
43 212.
44
45
46
47 44. World Health Organization. ICD-11. Prolonged Grief Disorder Criteria [Internet]. 2018
48
49 [geciteerd 14 oktober 2019]. Beschikbaar op: <https://icd.who.int/browse11/l->
50
51 [m/en#/http://id.who.int/icd/entity/1183832314](https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1183832314)
52
53
54
55
56
57
58
59
60

- 1
2
3 45. Boelen PA, Djelantik AAAMJ, de Keijser J, Lenferink LIM, Smid GE. Further validation of
4
5 the Traumatic Grief Inventory-Self Report (TGI-SR): A measure of persistent complex
6
7 bereavement disorder and prolonged grief disorder. *Death Stud.* 2019;43(6):351–64.
8
9
10
11 46. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress
12
13 Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation.
14
15 *J Trauma Stress.* 2015;28(6):489–98.
16
17
18
19 47. Boeschoten, M.A., Bakker, A., Jongedijk, R.A., Olff, M. PTSS checklist voor de DSM-5
20
21 (PCL-5). Diemen: Arq Nationaal Psychotrauma Centrum; 2014.
22
23
24
25 48. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.*
26
27 1983;67(6):361–70.
28
29
30
31 49. Spinhoven PH, Ormel J, Sloekers PPA, Kempen GIJM. A validation study of the Hospital
32
33 Anxiety and Depression scale (HADS) in different groups of Dutch subjects. *Psychol*
34
35 *Med.* 1997;27(2):363–70.
36
37
38
39 50. Boelen PA, van den Bout J. Anxious and depressive avoidance and symptoms of
40
41 prolonged grief, depression, and post-traumatic stress disorder. *Psychol Belg.*
42
43 2010;50(1–2):49–67.
44
45
46
47 51. Spielberger, C.D. State-Trait Anger Expression Inventory-2. *Psychological Assessment*
48
49 *Resources;* 1999.
50
51
52
53 52. Lievaart M, Franken IHA, Hovens JE. Anger Assessment in Clinical and Nonclinical
54
55 Populations: Further Validation of the State-Trait Anger Expression Inventory-2. *J Clin*
56
57 *Psychol.* 2016;72(3):263–78.
58
59
60

- 1
2
3 53. Schwarzer, R., Jerusalem, M. Generalized self-efficacy scale. In: Weinman, J., Wright, S.,
4
5
6 Johnston, M., redacteurs. Measures in health psychology: A user's portfolio Causal
7
8 and control beliefs. Windsor, UK: Nfer-Nelson; 1995. p. 35–7.
9
10
11 54. Horvath AO, Greenberg LS. Development and validation of the Working Alliance
12
13 Inventory. J Couns Psychol. 1989;36(2):223–33.
14
15
16
17 55. Vertommen, H., Vervaeke, G. Nederlandstalige experimentele vertaling van de Working
18
19 Alliance Inventory van Horvath en Greenberg. Leuven: KU; 1990.
20
21
22
23 56. Munder T, Wilmers F, Leonhart R, Linster HW, Barth J. Working Alliance Inventory-Short
24
25 Revised (WAI-SR): psychometric properties in outpatients and inpatients. Clin Psychol
26
27 Psychother. 2010;17(3):231–9.
28
29
30
31 57. Snijders, T.A.B., Bosker, R.J. Deviance tests. In: Snijders, T.A.B., Bosker, R.J.,
32
33 redacteurs. Multilevel analysis. London: SAGE Publications Ltd; 2012. p. 97–8.
34
35
36
37 58. Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful
38
39 change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–9.
40
41
42
43 59. Lenferink LIM, de Keijser J, Smid GE, Boelen PA. Cognitive therapy and EMDR for
44
45 reducing psychopathology in bereaved people after the MH17 plane crash: Findings
46
47 from a randomized controlled trial. Traumatology. 2020;
48
49
50
51 60. Glickman K, Shear, K.M., Wall MM. Therapeutic Alliance and Outcome in Complicated
52
53 Grief Treatment. Int J Cogn Ther. 2018;11(2):222–33.
54
55
56
57 61. Arjadi R, Nauta MH, Bockting CLH. Acceptability of internet-based interventions for
58
59 depression in Indonesia. Internet Interv. 2018;13:8–15.
60

- 1
2
3 62. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the
4
5 Community from 30 Countries between 1994 and 2014. *Sci Rep*. 2018;8(1):2861.
6
7
8
9 63. Lenferink, L.I.M., Boelen, P.A., Smid, G.E., Paap, M.C.S. The importance of harmonising
10
11 diagnostic criteria sets for pathological grief. *British Journal of Psychiatry*. in press;
12
13
14
15 64. Maciejewski PK, Prigerson HG. Prolonged, but not complicated, grief is a mental
16
17 disorder. *Br J Psychiatry*. 2017;211(4):189–91.
18
19
20
21 65. Wakefield JC. Should prolonged grief be reclassified as a mental disorder in DSM-5?:
22
23 reconsidering the empirical and conceptual arguments for complicated grief disorder. *J*
24
25 *Nerv Ment Dis*. 2012;200(6):499–511.
26
27
28
29
30
31
32
33

34 **Authors' contributions**

35
36 JdK is principal investigator. LL is executive researcher. JdK, PB, ME, and GS are grant
37
38 holders. LL developed the study design and wrote the ethics proposal and drafts of the
39
40 manuscript. JdK, ME, GS, and PB read, revised, and approved the drafts of the study design,
41
42 ethics proposal, and the manuscript.
43
44
45
46

47 **Funding statement**

48
49 Fund Victim Support subsidized this work (grant number: not applicable).
50
51

52 **Competing Interests Statement**

53
54
55
56 All authors declare to have no competing interests.
57
58
59
60

1
2
3 **Figure caption/legend**
4

5 **Figure 1.** Design of RCT
6

7
8 *Note.* CBT = cognitive behavioral therapy
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Design of RCT
356x148mm (96 x 96 DPI)

Supplementary File

Information for participants

Subject: Participation in study on the treatment of grief after a traffic accident

Dear sir/madam,

We ask you to take part in a scientific study. This participation is voluntary. In order to take part we do need your permission. You receive this information because you filled in a questionnaire some time ago, mapping the emotional consequences of the death of a loved one due to a traffic accident. You have indicated that you may be interested in taking part in a follow-up study exploring the effects of a treatment to learn to cope better with the death of your loved one.

Before you decide whether you want to take part in this study, you receive an explanation of what the study entails. Read this information carefully and ask the researcher to explain if you have questions.

1. General Information

This study is conducted by the University of Groningen, Utrecht University and Stichting Centrum '45. The study is financed by the Fonds Slachtofferhulp (Victim Support Fund). The study consists of participation in an online psychological treatment. The treatment is provided by therapists in various practices across the Netherlands. The medical-ethical review committee of the Universitair Medisch Centrum Groningen (Academic Medical Centre Groningen) has approved this study.

2. Purpose of the study

Those left behind after a traffic accident often indicate that the help provided does not sufficiently connect to their experiences. Therefore a treatment has been developed that is specifically intended for the partner, relatives and friends of someone who died due to a traffic accident. You can discuss with the therapist how you are coping with the loss and what the consequences of this loss are in your life. The aim of the treatment is to cope better with the loss. The treatment is part of a scientific study. The purpose of the study is to explore whether treatment leads to a reduction in emotional problems for those who lost someone due to a traffic accident.

3. Background of the study

During the treatment cognitive behavioural therapy will be used. Previous research has shown that cognitive behavioural therapy is the most effective treatment for reducing emotional problems after the loss of a loved one due to a natural cause (for instance illness). Cognitive behavioural therapy is mainly applied during individual sessions with a therapist (face-to-face treatment). Research has shown that cognitive behavioural therapy, offered via the internet (online treatment), also seems to be suitable for reducing problems after a natural death. More research is needed to find out whether this online version of cognitive behavioural therapy is also suitable for those who lost someone due to a traffic accident. The purpose of this study is to find out whether online cognitive behavioural therapy is accompanied by a reduction of emotional problems after the death of a loved one due to a traffic accident.

The online treatment is provided individually and consists of eight modules which you go through in twelve weeks. You will then have online contact with a therapist who will guide you during the treatment. In the Netherlands, a network of therapists has been trained in the online treatment of people

1
2
3 who lost someone due to a traffic accident. The therapists work at several treatment centres. The online
4 treatment is offered by Therapieland. Therapieland is a provider of psychological care via the internet.
5
6

7 **4. What participation entails**

8 If you take part, this will take at least 20 weeks in total for you.
9

10 *Screening*

11 First we will determine whether you can take part. You will be asked to fill in a questionnaire. The
12 questionnaire contains questions about emotional problems you may experience in response to the
13 passing away of your loved one due to a traffic accident. Also, questions are asked about previous
14 psychological help you may have received. The questionnaire is used to get a picture of the degree to
15 which you experience emotional problems.
16

17 If your completed questionnaire shows that you experience relatively few emotional problems, you
18 cannot take part in the study. You also cannot take part in the study if you have no access to the internet.
19 If your answers show that the treatment offered is not suitable for you, an alternative treatment will be
20 looked for in consultation with you.
21

22 It is possible that you filled out a questionnaire on this topic before. As problems can change over time,
23 we ask you to fill in a questionnaire once more. In this way we get a picture of the problems you are
24 experiencing at the moment.
25

26 *Treatment*

27 In order to be able to determine the effect of the treatment, participants are assigned to one of two
28 groups. The first group will start with the online treatment as soon as possible after registration. The
29 second group will start with the online treatment after a waiting period of 20 weeks. By adding a waitlist
30 group it can be determined that a reduction of problems is actually the result of the treatment, and not
31 of the passage of time. Which group you are assigned to will be determined by drawing lots. You and
32 we do not have any influence on the draw. We will let you know when your treatment starts.
33
34
35

36 *Measurements*

37 Before the treatment can start, you will be asked to fill in a questionnaire. This questionnaire will focus
38 on the problems you experience. We map these in order to be able to determine whether the treatment
39 might help you.
40

41 The therapist who will guide your online treatment will be informed of the results of this questionnaire
42 beforehand. In order to determine to what extent the treatment helps you, we ask you to fill in a
43 questionnaire not only beforehand, but also once during the treatment, after the last treatment session,
44 and 8 weeks after the treatment. People assigned to the waiting group will be asked to fill in an additional
45 questionnaire after 12 weeks and 20 weeks of waiting. In this way it can be determined whether the
46 treatment has been effective and what the short and long term effects of the treatment are. The filling
47 in will take approximately 10 to 30 minutes per measurement.
48
49
50

51 **5. What is expected from you**

52 In order to ensure that the study runs smoothly it is important that you adhere to the following
53 agreements. These agreements are that you:
54

- 55 ● contact the researcher in case of problems (the contact details are listed at the end of the
56 information letter);
- 57 ● keep all appointments with your therapist;
- 58 ● fill in the questionnaires before and after the treatment.
59
60

Besides, it is important that you contact the researcher if:

- your contact information changes
- you no longer wish to take part in the study

6. Possible negative effects

During the treatment you will actively engage with your thoughts and feelings about the loss. It is possible that feelings such as grief or loss or fatigue may temporarily increase in intensity. Filling in the questionnaire can also evoke emotional responses. When your problems increase to a great extent, you can contact the researcher via the contact details listed at the end of this letter.

7. Possible advantages and disadvantages

It is important that you carefully weigh the possible advantages and disadvantages before you decide to take part. The treatment may reduce your emotional problems, but this is not certain. Your participation will contribute to more knowledge about the treatment of emotional problems after the death of a loved one due to a traffic accident.

Disadvantages of taking part in the study may be:

- possible worsening of problems due to taking part in the treatment;
- possible worsening of problems due to filling in the questionnaire.

Participation in the study also means that:

- the study will cost you time;
- you will have to adhere to certain agreements.

These issues have all been described in section 4, 5 and 6 above.

8. If you do not wish to participate or if you wish to stop participating in the study

You decide whether or not to take part in the study. Participation is voluntary. If you do take part, you can always change your mind and stop participating after all, during the study as well. You do not have to give a reason for stopping. You do have to report this to the researcher immediately. The data collected up to that point will be used for the study.

If there is new information about the study that is important to you, the researcher will let you know this. We will then ask you if you continue to participate.

9. End of the study

Your participation in the study will end when: you will have filled in the questionnaire 8 weeks after the end of the treatment; you make the choice to stop participating; the researcher considers it better for you to stop participating; the government or the reviewing medical-ethical committee decide to end the study. The entire study will end when all participants are done. After processing all the data, the researcher will inform you of the most important outcomes of the study by means of a newsletter. You can indicate whether you wish to receive this newsletter at the end of the questionnaire.

10. Use and storage of your data

For this study your personal data will be collected, used and stored. This concerns data such as your name, address, date of birth and data related to your health. The collection, use and storage of your data is necessary to be able to answer the questions asked in this study and to publish the results. We ask your permission for the use of your data.

Confidentiality of your data

In order to protect your privacy, your data will get a code. Your name and other data which can identify you directly will be left out from this. Data can only be traced to you with the key to the code. The key to the code will remain safely stored at the local research institution. The data sent to eventual other parties involved only contain the code, but not your name or other data with which you can be identified. In reports and publications on the study the data cannot be traced to you either.

Access to your data for checks

Some people may get access to all your data at the research location, including the data without code. This is necessary to be able to check whether the study has been done properly and reliably. People who will gain access to your data for checking purposes will be the researchers Lonneke Lenferink, a research assistant and Jos de Keijser, the committee monitoring the safety of the study and international supervising authorities. They will keep your data secret. We ask you to give your permission for this access.

Data retention period

Your data must be retained at the research location for 15 years. They are stored in order to be able to make new provisions related to this study in the course of this study.

Withdrawal of permission

You can always withdraw your permission for the use of your personal data again. The research data collected up to the moment you withdraw permission will still be used in the study.

Further information about your rights regarding data processing

For general information about your rights you can contact the person responsible for processing your personal data. For this study this is Lonneke Lenferink (University of Groningen). In case of questions or complaints regarding the processing of your personal data we recommend that you contact her.

11. Insurance for test subjects

An insurance has been taken out for everyone taking part in the study. The insurance covers damage from the study. You can report damage to the researchers.

12. Informing family doctor/GP

We do not share information about your participation in the study with your family doctor/GP.

13. Compensation for participation

1
2
3
4 Participation in the online treatment is free of charge.
5
6

7 **14. Do you have any questions?**

8
9 In case of general questions regarding the study you can contact the researcher assistant. If you have
10 complaints about the study, you can discuss this with the researchers or with your treating therapist. If
11 you prefer not to do this, you can contact the University of Groningen.
12
13

14 **15. Signing the consent form**

15
16 Below you find a 'Declaration of consent for participation in research into the treatment of grief after a
17 traffic accident', on which you can indicate whether you wish to take part in the study. With your
18 permission you indicate that you have understood the information and that you agree to participate in
19 the study.
20
21

22
23 After you have filled in this declaration, you can start filling in the questionnaire. Approximately within
24 four weeks after filling in the questionnaire we will let you know by email or by phone whether you
25 qualify for the treatment. When you qualify for treatment, you will receive the outcome of the draw
26 which indicates whether you have been assigned to a group that can start with the online treatment as
27 soon as possible, or whether you have been assigned to the group that needs to wait for 20 weeks before
28 the start of the online treatment.
29

30
31 If you have any further questions, you can contact us via the details below.
32

33 Kind regards,
34

35
36 [name research assistant]
37

38 Research assistant University of Groningen
39

40
41
42 Lonneke Lenferink
43

44 Post-doctoral researcher University of Groningen and Utrecht University
45
46
47

48 **Contact Details**

49
50 General questions about the study: [name research assistant], info@rouwnaverkeersongeval.nl
51

52
53 Questions regarding the protection of your data, your rights or complaints: please contact Lonneke
54 Lenferink, i.m.lenferink@rug.nl.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Consent Form
for participation in research on treatment of grief after a traffic accident

- I have read the information letter. I also had the opportunity to ask questions. My questions have been answered adequately. I had enough time to decide whether to participate or not.
- I know that participation is voluntary. I also know that I can decide at any moment not to participate after all or to stop participating in the study. I do not have to give a reason for this.
- I give permission for collecting and using my data to answer the research question of this study.
- I know that some people may gain access to all of my data for the purpose of checks of this study. Those people are listed in this information letter. I give permission for this access by these people.
- I wish to participate in this study.

Name of participant:

Email address:

Phone number:

Signature of participant:

Date: __ / __ / __

The researcher, Lonneke Lenferink, hereby declares that the test subject has been fully informed about the aforementioned study.

If information becomes known during the study which might influence the consent of the participant, the participant will be timely informed about this.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

			Page
	Reporting Item		Number
Administrative information			
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym		1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	3
2			name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	n/a
7	data set		Registration Data Set	
8				
9				
10				
11				
12	Protocol version	#3	Date and version identifier	n/a
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	32
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	32
21	responsibilities:			
22				
23	contributorship			
24				
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	n/a
29	responsibilities:			
30				
31	sponsor contact			
32				
33	information			
34				
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	32
39	responsibilities:		design; collection, management, analysis, and	
40			interpretation of data; writing of the report; and the	
41	sponsor and funder		decision to submit the report for publication, including	
42			whether they will have ultimate authority over any of	
43			these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	n/a
53	responsibilities:		coordinating centre, steering committee, endpoint	
54			adjudication committee, data management team, and	
55	committees			
56				
57				
58				
59				
60				

other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-7
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	4-7
Objectives	#7	Specific objectives or hypotheses	8
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	8-9
Methods:			
Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	10

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	11
2			applicable, eligibility criteria for study centres and	
3			individuals who will perform the interventions (eg,	
4			surgeons, psychotherapists)	
5				
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to allow	12-13
12			replication, including how and when they will be	
13	description		administered	
14				
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	19
20			interventions for a given trial participant (eg, drug dose	
21	modifications		change in response to harms, participant request, or	
22			improving / worsening disease)	
23				
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention protocols,	10
30			and any procedures for monitoring adherence (eg, drug	
31	adherence		tablet return; laboratory tests)	
32				
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	16-17
37			permitted or prohibited during the trial	
38	concomitant care			
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including the	14-17
43			specific measurement variable (eg, systolic blood	
44			pressure), analysis metric (eg, change from baseline, final	
45			value, time to event), method of aggregation (eg, median,	
46			proportion), and time point for each outcome. Explanation	
47			of the clinical relevance of chosen efficacy and harm	
48			outcomes is strongly recommended	
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including any	10
2			run-ins and washouts), assessments, and visits for	
3			participants. A schematic diagram is highly recommended	
4			(see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	11
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any sample	
14			size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant enrolment to	10
22			reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	8-9
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction (eg,	
40			blocking) should be provided in a separate document that	
41			is unavailable to those who enrol participants or assign	
42			interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence (eg,	8-9
54	concealment		central telephone; sequentially numbered, opaque,	
55				
56				
57				
58	mechanism			
59				
60				

sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Allocation: [#16c](#) Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 9

Blinding (masking) [#17a](#) Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how 9

Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial n/a

Methods: Data collection, management, and analysis

Data collection plan [#18a](#) Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 14-17

1	Data collection plan:	#18b	Plans to promote participant retention and complete	n/a
2				
3	retention		follow-up, including list of any outcome data to be	
4			collected for participants who discontinue or deviate from	
5			intervention protocols	
6				
7				
8				
9				
10				
11	Data management	#19	Plans for data entry, coding, security, and storage,	19
12			including any related processes to promote data quality	
13			(eg, double data entry; range checks for data values).	
14			Reference to where details of data management	
15			procedures can be found, if not in the protocol	
16				
17				
18				
19				
20				
21				
22				
23	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary	17-20
24			outcomes. Reference to where other details of the	
25			statistical analysis plan can be found, if not in the protocol	
26				
27				
28				
29				
30				
31	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and	17-20
32	analyses		adjusted analyses)	
33				
34				
35				
36	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	17-20
37	population and		adherence (eg, as randomised analysis), and any	
38	missing data		statistical methods to handle missing data (eg, multiple	
39			imputation)	
40				
41				
42				
43				
44				
45				
46	Methods: Monitoring			
47				
48				
49	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	19
50	formal committee		summary of its role and reporting structure; statement of	
51			whether it is independent from the sponsor and	
52			competing interests; and reference to where further	
53				
54				
55				
56				
57				
58				
59				
60				

1 details about its charter can be found, if not in the
 2
 3 protocol. Alternatively, an explanation of why a DMC is
 4
 5 not needed
 6
 7

8	Data monitoring:	#21b	Description of any interim analyses and stopping	19
9				
10	interim analysis		guidelines, including who will have access to these	
11				
12			interim results and make the final decision to terminate	
13				
14			the trial	
15				
16				
17				
18	Harms	#22	Plans for collecting, assessing, reporting, and managing	19
19				
20			solicited and spontaneously reported adverse events and	
21				
22			other unintended effects of trial interventions or trial	
23				
24			conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if	19
29				
30			any, and whether the process will be independent from	
31				
32			investigators and the sponsor	
33				
34				
35	Ethics and			
36				
37	dissemination			
38				
39				
40				
41	Research ethics	#24	Plans for seeking research ethics committee / institutional	19
42				
43	approval		review board (REC / IRB) approval	
44				
45				
46	Protocol	#25	Plans for communicating important protocol modifications	19
47				
48	amendments		(eg, changes to eligibility criteria, outcomes, analyses) to	
49				
50			relevant parties (eg, investigators, REC / IRBs, trial	
51				
52			participants, trial registries, journals, regulators)	
53				
54				
55				
56				
57				
58				
59				
60				

1	Consent or assent	#26a	Who will obtain informed consent or assent from potential	19
2			trial participants or authorised surrogates, and how (see	
3			Item 32)	
4				
5				
6				
7				
8				
9	Consent or assent:	#26b	Additional consent provisions for collection and use of	n/a
10			participant data and biological specimens in ancillary	
11	ancillary studies		studies, if applicable	
12				
13				
14				
15				
16	Confidentiality	#27	How personal information about potential and enrolled	19
17			participants will be collected, shared, and maintained in	
18			order to protect confidentiality before, during, and after	
19			the trial	
20				
21				
22				
23				
24				
25				
26	Declaration of	#28	Financial and other competing interests for principal	32
27			investigators for the overall trial and each study site	
28	interests			
29				
30				
31				
32	Data access	#29	Statement of who will have access to the final trial	19
33			dataset, and disclosure of contractual agreements that	
34			limit such access for investigators	
35				
36				
37				
38				
39	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	19
40			compensation to those who suffer harm from trial	
41	trial care		participation	
42				
43				
44				
45				
46				
47	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	19-20
48			results to participants, healthcare professionals, the	
49	trial results		public, and other relevant groups (eg, via publication,	
50			reporting in results databases, or other data sharing	
51			arrangements), including any publication restrictions	
52				
53				
54				
55				
56				
57				
58				
59				
60				

1 Dissemination policy: [#31b](#) Authorship eligibility guidelines and any intended use of n/a
 2
 3 authorship professional writers
 4
 5

6 Dissemination policy: [#31c](#) Plans, if any, for granting public access to the full n/a
 7
 8 reproducible protocol, participant-level dataset, and statistical code
 9
 10 research
 11
 12

13 Appendices

14
 15
 16
 17 Informed consent [#32](#) Model consent form and other related documentation 10
 18
 19 materials given to participants and authorised surrogates
 20
 21

22
 23 Biological specimens [#33](#) Plans for collection, laboratory evaluation, and storage of n/a
 24
 25 biological specimens for genetic or molecular analysis in
 26
 27 the current trial and for future use in ancillary studies, if
 28
 29 applicable
 30
 31

32
 33 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
 34
 35 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
 36
 37 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60